 
Protocol I8F -MC-GPGB  (a) 
 
A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes  
Mellitus  
[STUDY_ID_REMOVED] 
Approval Date: 28- Nov-2017 
I8F-MC-GPGB (a)Clinical Protocol Page 1
LY3298176Approval Date: 17 -Mar-2017 GMTProtocol I8F-MC-GPGB (a)
A Phase 2 Study of Once -WeeklyLY3298176 Compared with 
Placebo and Dulaglutide in Patients with Type 2 Diabetes 
Mellitus
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_221008] s not involved in the clinical investigation of 
LY3298176, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries .  
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FO IA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3298176
This is a randomized, double -blind, parallel, placebo -and active comparator -controlled, 
Phase 2 ,multicenter, multi -country study in patients with type 2 diabetes.
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_221033].
Approval Date: 28-Nov-2017 GMT
I8F-MC-GPGB (a)Clinical Protocol Page 2
LY3298176Table of Contents
Section Page
Protocol  I8F-MC-GPGB(a) A Phase [ADDRESS_265328] ivities....................................................................................................... 11
3. Introduction ...................................................................................................................... 16
3.1. Study  Rati onale ............................................................................................................ 16
3.2. Background .................................................................................................................. 16
3.3. Benefit /Risk Assessment .............................................................................................. [ADDRESS_265329] ions/Requirements ...................................................................... 34
7.3. Blinding ....................................................................................................................... 34
7.4. Dosage Modification .................................................................................................... 35
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 35
7.6. Treatment Compliance .................................................................................................35
7.7. Concomitant Therapy ................................................................................................... 36
I8F-MC-GPGB (a)Clinical Protocol Page 3
LY32981767.8. Treatment after the End of the Study ............................................................................ 37
7.8.1. Speci al Treatm ent Consi derat ions (Rescue Therapy) ............................................ [ADDRESS_265330] to Follow -Up........................................................................................................ 40
9. Study Assessments and Procedures ................................................................................... 41
9.1. Efficacy Assessments ................................................................................................... 41
9.1.1. Primary Efficacy  Assessments ............................................................................. 41
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 41
[IP_ADDRESS]. Exploratory  Efficacy  Assessments .................................................................. 41
9.1.3. Appropriateness of Assessments .......................................................................... 42
9.2. Adverse Events ............................................................................................................ 42
9.2.1. S erious Adverse Events ........................................................................................ 43
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 44
[IP_ADDRESS]. Adverse Events of Special Interest .................................................................. 44
[IP_ADDRESS].1. Inject ion Site Reacti ons ............................................................................ 44
[IP_ADDRESS].2. Hypersensi tivity Reacti ons........................................................................ 44
[IP_ADDRESS].3. Hypoglycemia ........................................................................................... 44
[IP_ADDRESS].4. Nausea, Vomit ing, and Diarrhea ............................................................... 45
[IP_ADDRESS].5. Acute Pancreat itis..................................................................................... 45
[IP_ADDRESS].6. Major Adverse Cardio vascular Events ...................................................... 46
[IP_ADDRESS].7. Thyroid C-Cell Hyperpl asia and C -Cell Neoplasms .................................. 47
9.2.2. Com plaint Handling ............................................................................................. 47
9.3. Treatment of Overdose .................................................................................................47
9.4. Safety........................................................................................................................... 47
9.4.1. Electrocardiograms .............................................................................................. 47
9.4.2. Vital Signs ........................................................................................................... 49
9.4.3. Laboratory  Tests .................................................................................................. 49
9.4.4. Safety Moni toring ................................................................................................ 49
9.5. Pharmacokinet ics......................................................................................................... 50
9.6. Pharmacodynamics ...................................................................................................... 50
9.7. Pharmacogenet ics......................................................................................................... 50
9.7.1. Who le Blood Samples for Pharmacogenet ic Research .......................................... 50
9.8. Biomarkers ................................................................................................................... 51
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265331] ical Considerat ions........................................................................ 55
10.3.2. Treatment Group Comparabilit y........................................................................... 56
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 56
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 56
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 56
[IP_ADDRESS]. Treatment Compliance .................................................................................... 56
10.3.3. Efficacy Analyses ................................................................................................ 56
[IP_ADDRESS]. Primary Analyses ........................................................................................... 56
[IP_ADDRESS]. Supporting Analyses of Primary  Outcom e...................................................... 57
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 57
[IP_ADDRESS].1. Secondary  Analysis on Primary  Efficacy Endpoint ................................... 57
[IP_ADDRESS].2. Analyses on Secondary  Efficacy Endpoints ............................................... 58
10.3.4. Safety Analyses .................................................................................................... 59
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 59
[IP_ADDRESS]. Adverse Events ............................................................................................... 59
[IP_ADDRESS]. Vital Signs
...................................................................................................... 60
[IP_ADDRESS]. Laboratory  Measures ...................................................................................... 60
[IP_ADDRESS]. Evaluat ion of Immunogenicit y........................................................................ 60
[IP_ADDRESS]. Electrocardiograms ......................................................................................... 60
[IP_ADDRESS]. Adverse Events of Special Interest .................................................................. 61
[IP_ADDRESS]. Hypoglycemic Epi[INVESTIGATOR_1841] ................................................................................. 61
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 62
10.3.6. Other Analyses ..................................................................................................... 62
[IP_ADDRESS]. Health Outcom e/Quali ty of Life Analyses ...................................................... 62
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 62
[IP_ADDRESS]. Exploratory  Analyses ..................................................................................... 62
10.3.7. Interim Analyses .................................................................................................. 63
11. References ........................................................................................................................ 64
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265332] Administration and Treatment Regimens .................. 31
Table GPGB.3. Reco mmended Dose Titration Schedulea........................................................ 31
Table GPGB.4. Dose –Response Assumpt ion Used in Sample Size Determinat ion.................. 54
Table GPGB.5. Definit ions of Populat ions to Be Analyzed in Study  GPGB ........................... 54
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265333] of Figures
Figure Page
Figure GPGB.1. Illustrati on of  study  design for Clinical Protocol I8F -MC-GPGB. .................. 21
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265334] of A ppendices
Appendix Page
Abbreviat ions and Definit ions........................................................................ 66 Appendix 1.
Clinical Laboratory  Tests ............................................................................... 70 Appendix 2.
Study  Governance Considerat ions.................................................................. 72 Appendix 3.
Hepati c Moni toring Tests for Treatment- Emergent Abnormalit y.................... 76 Appendix 4.
World Heal th Organizat ion Classification for Diabetes .................................. 77 Appendix 5.
Pharmacokinetics Schedule of Events ............................................................ 78 Appendix 6.
Contraceptive Methods .................................................................................. 79 Appendix 7.
World Heal th Organizat ion Standardized Protocols for the Appendix 8.
Measurement of Height and Weigh t............................................................... 80
Protocol  Amendment I8F -MC-GPGB(a) Summary:  A Phase 2 Study of Appendix 9.
Once -Weekly  LY3298176 Compared wi th Placebo and Dul aglut ide in 
Patients wi th Type 2 Di abetes Melli tus.......................................................... 81
I8F-MC-GPGB (a)Clinical Protocol Page 8
LY32981761.Synopsis
Title of Study:
A Phase 2 Study of Once -Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with 
Type 2 Diabetes Mellitus
Rationale: 
Study I8F -MC -GPGB is a 26 -week Phase 2 study designed to examine the safety, efficacy, and pharmacokinetics 
(PK)/pharmacodynamics ( PD)of 4dose levels of once wee kly(QW) LY3298176 compared with QW dulaglutide 
1.5mg and QW placebo in patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control 
with diet and exercise with or without a stable dose of metformin.  The primary endpoint will be the effect on 
hemoglobin A1c ( HbA1c).  These data will support dose selection for Phase 3.
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To demonstrate a dose –response relatio nship of QW 
subcutaneous injections of LY3298176 on HbA1c 
change from baseline relative to placebo, in patients 
with T2DM inadequately controlled with diet and 
exercise alone or treated with a stable dose of 
metformin.The change in HbA1c from base line to [ADDRESS_265335] of LY3298176 versus 
dulaglutide (and to compare the effect of each versus 
placebo) on:
The m ean body weight change from baseline 
to 12 and 26 weeks
The percentage of patients with 5% or 
greater body weight loss at 26 weeksThe change in mean body weight from 
baseline to 12 and 26 weeks
The percentage of patients with 5% or 
greater body weight loss from baseline to 
26weeks
The c hange f rom baseline of HbA1c at 
12weeksThe chan ge in HbA1c from baseline to 
12weeks
The p ercentage of patients with 10% or 
greater body weight loss at 26 weeks
The percentage of patients reaching the 
HbA1c target of 6.5% and of 7.0%The percentage of patients with 10% or 
greater body weight loss from baseline to 
26weeks
The percentage of patients reaching the 
HbA1c target of 6.5% and of 7.0%
The c hange f rom baseline of fasting blood 
glucose (FBG) at 12 and 26 weeks
The c hange f rom baseline to 26 weeks in 
high-density lipoprotein cholesterol, total 
cholesterol, triglycerides, and low -density  
lipoprotein cholesterolThe change in FBG from baseline to 12 and 
26weeks
The change in lipi[INVESTIGATOR_81059] 
26weeks
The waist circumference The change from baseline to 12 and 
26weeks
I8F-MC-GPGB (a)Clinical Protocol Page 9
LY3298176Objectives Endpoints
Secondary (continued)
Safety and tolerability, including gastrointestinal
tolerability, incidence and rate of hypoglycemia, 
hypersensitivity reactions, and pancreatic safetyAdverse events and glucose data
To evaluate the development of treatment -emergen t 
anti-drug antibodies to LY 3298176Number of patients testing p ositive for 
anti-LY3298176 antibodies
To assess the PK and PD of LY3298176 and potential 
patient factors that may influence its PK and PDPK and PD
To assess the relationship between LY32981 76 dose 
and/o r exposure and key efficacy and safety 
measures , where applicableDose -exposure–response analyses
Summary of Study Design :
Study GPGB is a multicenter, randomized, double -blind, parallel, placebo -and active comparator -controlled Phase 2 
trial in patients with T2DM who failed to achieve adequate glycemic control on diet and exercise alone or on a 
stable dose of metformin ( 1000 mg/day for at least 3 months prior to Visit 1).
Treatment Arms and Duration:
There are 6 treatment arms, including placebo, 4 dose levels of LY3298176, and dulaglutide 1.5 mg.
Number of Patients :
There will be 540 patients screened wi th the goal of randomizing 300 patients and having 45 patients per treatment 
arm who complete the study .
Statistical Analysis:
Efficacy :  The primary efficacy outcome of HbA1c change from baseline to the 26-week endpoint will be analyzed 
using a Bayesian dose –response model.  Analyses will be performed on the modified inte nt-to- treat (mITT) analysis 
set.  Supportive analysis of the primary efficacy outcome for the mITT dataset will be the mixed model for repeated 
measures (MMRM) with body mass index (<30, 30), metformin use, treatment, visit, and treatment -by-visit 
interaction as fixed effects, baseline Hb A1c as a covariate, and patient as a random effect.  Additional covariates 
may be added and will be detailed in the statistical analysis plan.
The mean weight change from baseline at 12 and 26weeks along with the mean change from baseline of HbA1c at 
12 w eeks will be analyzed using similar dose –response models as the primary analysis. The percentage of patients 
with 5% (and with 10%) body weight loss , the percentage of patients reaching the HbA1c target of 6.5% (and of 
7.0%) at 26weeks , and the proportion of patients requiring rescue therapy will be analyzed using a logistic 
regression analysis with fixed effects of treatment and strata , and baseline as a covariate .  The change from baseline 
of FBG , 
self-monitoring of blood glucose levels , waist circu mference , mean percentage change in lipi[INVESTIGATOR_221009] 12and [ADDRESS_265336] growth factor -21, adiponectin, -hydroxy  buty rate, free fatty acids, 
glycerol, monocyte chemoattractant protein -1 (MCP -1), glucagon, C-peptide, and insuli n levels will be calculated 
I8F-MC-GPGB (a)Clinical Protocol Page 10
LY3298176using a similar MMRM -based model to the one used for the supporting primary analysis.  Summaries will include 
descriptive statistics for continuous measures (sample size, mean, standard deviation [SD], median, minimum, and 
maxim um) and for categorical measures (sample size, frequency, and percentage).
Pharmacokinetics/Pharmacodynamics :  LY3298176 concentration data will be analyzed using a population PK 
approach via nonlinear mixed-effects modeling with the NONMEM software.  The relationships between 
LY3298176 dose and/or concentration and efficacy, tolerability, and safety, as well as biomarker s, will be 
characterized if exploratory analyses of the PD data warrant further PK/PD analyses upon review.  Such analyses 
may include, but are not necessarily limited to, QTc interval, blood pressure, heart rate , glucose, HbA1c, insulin, 
nausea/vomiting, etc .  In addition, the relationship between biomarkers and LY3298176 efficacy will be analyzed, if 
deemed appropriate.  If positive antibody titers to LY3298176 are observed, the relationship between LY3298176
PK or any relevant PD parameters and antibody tit er will be performed.
Safety :  The summary  statistics for continuous variables will be sample size, mean, SD, median, minimum, and 
maximum.  The summary statistics for categorical variables will be sample size, frequency, and percentage.  
Exposure to each therapy during the treatment period of the study will be calculated for each patient and 
summarized by [CONTACT_1570].  Additional analyses, such as concentration –safety lab plots , may be performed if 
warranted upon review of the data.
I8F-MC-GPGB (a)Clinical Protocol Page 11
LY32981762.Schedule of A ctivities
Study Phase ScreenLead -
inRandomiz e Treatment PhaseFollow
upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Week of Treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study Day/(Dose 
number)0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13) 112/(17)140/(21) 168/(25) 182/(27)
Visit Window (days) ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
PK Specific VisitaX X X X
Administrative
Informed consent X
Diabetes /medical
history /therapyX
Inclusion/Exclusion X X
Preexisting conditions X X
Randomization X
IWRS X X X X X X X X X X X X
Drug accountability X X X X X X X X X X
BG meter/supplies, if 
neededX X X X X X X X
BG meter, instructions X X
Diet, exercise, BG 
counselingX
Study diary, dispense X X X X X X X X X X X
Review patient diaries 
for BG values, AEs, 
hypoglycemic or 
hyperglycemic eventsX X X X X X X X X X X X X
Subcutaneous injection 
trainingX X
I8F-MC-GPGB (a)Clinical Protocol Page 12
LY3298176Study Phase ScreenLead -
inRandomize Treatment PhaseFollow
upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Week of Treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study day/(Dose 
number)0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13) 112/( 17 ) 140/(21) 168/(25) 182/(27)
Visit Window (days) ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
PK Specific VisitaX X X X
Study drug and injection 
supplies, dispenseX X X X X X X X X X
Health habits (alcohol 
use y es/no, tobacco use 
current/past)X
Patient returns unused 
study drug suppliesX X X X X X X X
Study drug, assess 
complianceX X X X X X X X
Patient Demographics
Age X
Gender X
Race/Ethnicity X
Clinical Variables
Physical examination X X X
Symptom -driven 
physical examX X X X X X X X X X
Height X
Weight X X X X X X X X X X X X
Waist circumference X X X X X X X X X X
Vital signs (BP and PR) X X X X X X X X X X X X
Antidiabetic medication X X X X X X X X X X X X X X
Concomitant medication X X X X X X X X X X X X X X
I8F-MC-GPGB (a)Clinical Protocol Page 13
LY3298176Study Phase ScreenLead -
inRandomize Treatment PhaseFollow
upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Week of Treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study day/(Dose 
number)0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13) 112/(17)140/(21) 168/ (25)182/ (27)
Visit Window (days) ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
PK Specific VisitaX X X X
Other
ECGsbX X XcXcXcXcX X
Evaluatio n of Injection 
Site ReactionsX X X X X X X X X X X
APPADL and IW -SP 
questionnairesX X X X
Diagnostics (Safety)
Screening Laboratory 
Testsd X
Pregnancy testeX X
Estradiol, FSH, LHfX
Chemistry panel X X X X X X X
Lipase and amylase X X X X X X X X X X X X X
Lipid panel X X X X X X
eGFR X X X X X X X
Hematology X X X X X X
Urinaly sis X X X X X
Urine albumin, 
creatinine, UACRX X X X X
I8F-MC-GPGB (a)Clinical Protocol Page 14
LY3298176Study Phase ScreenLead -
inRandomize Treatment PhaseFollow
upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Week of Treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study day/(Dose 
number)0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13) 112/( 17 ) 140/(21) 168/(25) 182/(27)
Visit Window (days) ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
PK Specific VisitaX X X X
Diagnostics (Efficacy )
Calcitonin X X X X X
HbA1c X X X X X X X X X X X X X
Fasting glucose X X X X X X X X
Fasting insulin and 
c-peptideX X X X X
Fasting glucagon X X X X X
Total and active 
GLP-1/GIPX X X X X X
Remind Patients about 
7-point SMBGX X X XX
7-point SMBG XgX X X X
Osteopontin, FGF -21
(active) , Adiponectin, 
-hydroxy  buty rate, 
glycerol, free fatty acids,
MCP -1, CTX -1, P1NP, 
osteocalcinX X X X
I8F-MC-GPGB (a)Clinical Protocol Page 15
LY3298176Study Phase ScreenLead -
inRandomiz e Treatment PhaseFollow
upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Week of Treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study day/(Dose 
number)0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13) 112/( 17 ) 140/(21) 168/(25) 182/(27)
Visit Window (days) ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
PK Specific VisitaX X X X
Pharmacogenetic stored 
samplesX
Nonpharmacogenetic 
stored samplesX X X X X
Immunogenicity testing X X X X X X X X
PK sample for 
Immunogenicityh XhXhXh
Pharmacokinetics ( see 
PK schedule)a Xa*XaXaXaXa*Xa*XacXa*Xa
Abbreviations:  AE = adverse event; APPADL = Ability to Perform Physical Activities of Daily Living; BG = blood glucose; BP = blood pressure; d = day; 
eGFR = estimated glomerular filtration rate; ECG = electrocardiogram; FGF -21 = fibrobla st growth factor -21; FSH = fol licle-stimulating hormone; 
GLP-1 = glucagon -like peptide -1; GIP = glucose -dependent insulinotropic peptide; HbA1c = hemoglobin A1c; IWRS = Interactive Web Response System; 
IW-SP = Impact of Weight on Self -Perception; LH = lute inizing hormone; PK = pharmacokinetics; PR = pulse rate; SMBG = self -monitoring of blood 
glucose; UACR = urine albumin -to-creatinine ratio.
*Indicates PK samples to be collected predose.
aSee Pharmacokinetics Schedule of Events, Appendix 6 .
bECGs should becollected centrally at Visits 3, 10, 11, 12, 16, and 801, and locally at screening and early termination.
cECG should be collected immediately prior to PK sample collectio n.
dScreening laboratory tests include serum hepatitis B surface Ag, hepatitis C antibody (Ab), and human immunodeficiency virus Abtests for all patients.
eSerum pregnancy test will be performed by [CONTACT_82408] [ADDRESS_265337] may be performed at the investigator’s discretion if pregnancy is suspected during the study (local laboratory ).
fCollect serum estradiol, FSH, and LH in women whose menopausal status nee ds to be determined.
gTwo baseline collections during the lead -in period.
hPK samples specifically for immunogenicity.
I8F-MC-GPGB (a)Clinical Protocol Page 16
LY32981763.Introduction
3.1. Study Rationale
Study  I8F-MC-GPGB is a 26-week Phase 2 study  designed to examine the safet y, efficacy ,and 
pharmacokinet ics (PK)/ pharmacodynamics ( PD) of
4dose l evels o f once weekly (QW) 
subcutaneously administered LY3298176 compared wi th QW subcutaneously  administered 
dulaglut ide 1.5 mgand QW placebo in p atients with type2 diabetes mellitus (T2DM) who have 
inadequate glycemic control wit h diet and exercise with or wi thouta stable dose of met formin.  
The primary  object ive will be the effect on hemoglobin A1c ( HbA1c).  These data will support 
dose sel ection for Phase 3.
3.2. Background
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
CCI
I8F-MC-GPGB (a)Clinical Protocol Page 17
LY3298176 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
I8F-MC-GPGB (a)Clinical Protocol Page 18
LY32981763.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks ,serious adverse events (SAEs), 
and reasonably ant icipated AEs ofLY3298176 may be found in the Investigator’s Brochure (IB). 
Inform ation on AEs expected to be related to the investigational product may be found in 
Secti on7(Development Core Safet y Inform ation)of the IB.  Informat ion on SAEs that are 
expected in the study  popul ation independent of drug exposure will be assessed by [CONTACT_221034] , periodically during the course of the study, and may be found in Section 6 (Effects in 
Hum ans) of  the IB.
More detailed informat ion about the known and expected benefits and risks of dulaglut ide may 
be found in the USPI [INVESTIGATOR_221010] (Trulicit yUSPI, 2015; Trulicit ySmPC, 2016) .
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265338] ives and endpo ints ofthe study .
Table GPGB. 1
. Objectives and Endpoints
Objectives Endpoints
Primary
The primary objective of this study is to demonstrate a 
dose–response relationship of QW SC injections of 
LY3298176 on HbA1c change from baseline relative to 
placebo, in patients with T2DM inadequately controlled 
with diet and exercise alone or treated with a stable dose 
of metformin.The change in HbA1c from baseline to [ADDRESS_265339] of LY3298176 versus 
dulaglutide (and to compare the effect of each versus 
placebo) on:
The m ean body weight change from baseline to 12 
and 26 weeks
The p ercentage of patients with 5% or greater body 
weight loss at 26 weeksThe change in mean body weight from baseline to 
12 and 26 weeks
The percentage of patients with 5% or greater body 
weight loss from baseline to 26 weeks
The c hange f rom baseline of HbA1c at 12 weeks The change in HbA1c from baseline to 12 weeks
The p ercentage of patients with 10% or greater 
body weight loss at 26 weeks
The percentage of patients reaching the HbA1c 
target of 6.5% and of 7.0%.The percentage of patients with10% or greater body 
weight loss from baseline to 26 weeks
The percentage of patients reaching the HbA1c 
target of 6.5% and of 7.0%
The c hange f rom baseline of fasting blood glucose
(FBG) at 12 and 26 weeks
The c hange f rom baseline to 26 weeks in high -
density  lipoprotein cholesterol (HDL -C), total 
cholesterol, triglycerides, and low -density  
lipoprotein cholesterol (LDL -C)The change in FBG from baseline to 12 and 
26weeks
The change in lipid laboratory data from baseline to 
26weeks
The waist circumference Change f rom baseline to 12 and 26 weeks
Safety and tolerability, including GI tolerability, 
incidence and rate of hypoglycemia, hypersensitivity  
reactions, and pancreatic safetyAE reports and evaluation of laboratory data
To evaluate the development of treatment -emergent anti-
drug antibodies to LY3298176Number of pat ients testing positive for 
anti-LY3298176 antibodies
To assess the PK and PD of LY3298176 and potential 
patient factors that may influence its PK and PDPK and PD
To assess the relationship between LY3298176 dose 
and/o r exposure and key efficacy and safety measures , 
where applicableDose -exposure–response analyses
I8F-MC-GPGB (a)Clinical Protocol Page 20
LY3298176Tertiary/Exploratory
Evaluate the effect of LY3298176 compared with 
placebo and dulaglutide on:
Change f rom baseline of 7-point self-monitoring of 
blood glucose (SMBG )profiles at 4, 12, 26, and 
30week s
Biomarkers The change in SMBG profile from baseline to 4, 12, 
26, and 30 weeks
The change from baseline to 12 and 26 weeks
Patient- reported outcomes (PRO) The change from baseline to 12 and 26 weeks
Pharma cogenetic objectives are
a.To evaluate genetic variants in genes 
in the glucagon signaling pathway and 
GIP/GLP -1-associated genes for 
association with efficacy responses to 
LY3298176 such as change from 
baseline in HbA1c, fasting glucose, 
body weight, and body mass index 
(BMI).
b.To evaluate the association of genetic 
variants in the glucagon sign aling 
pathway and GIP/GLP -1-associated 
genes with other PDand clinical 
endpoints of interest (including 
circulating glucagon levels, BP, serum 
amylase and lipase, GI tolerance, lipid 
metabolism, bone metabolism, etc.).
c.To investigate the genetic variants 
associated with dulaglutide treatment 
response (identified from dulaglutide 
clinical trials) on the efficacy and 
safety endpoints in response to 
LY3298176.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265340] t ype2 diabetes.
Figure GPGB. 1illustrates the study  design , including recommended dose titration scheme (see 
Secti on7.1for details on dose titration) .
Illustration of study  design for Protocol I8F -MC-GPGB
Week
Visit-3-2 0 1234 5 6 23242526 19 20 21 22 15161718 11121314 78 9 10 3026 WeeksLY Placebo + Dulaglutide 1.5 mgLY 15 mg + Dulaglutide PlaceboLY 10 mg + Dulaglutide PlaceboLY 5 mg + Dulaglutide PlaceboLY 1 mg + Dulaglutide PlaceboLY Placebo + Dulaglutide Placebo
12 3 46 8 1529
14 13 11 10 8012728
16
PK Visit 5 7 9 12Lead-inScreeningFollow Up 26 Week Treatment Period
4 Weeks5, 5 mg
5, 5, 10, 10, 10, 10 mg1 Week
2 WeeksStudy Period 1 Study Period 2 Study Period 3
Randomization End of Treatment
Figure GPGB. 1. Illustrat ion of study design for Clinical Protocol I8F -MC-GPGB .
All LY3298176 dose l evels above 5 mg will be reached through dose titration (see Sect ion7.1).
Study  procedures and timing for the lead-in,blinded treatment ,and follow -up phases are 
outlined in Section2.  Eligibilit y for this study  will be determined at a screening visit (Visit 1).  
Screening procedures will be performed on approximately Day 21according to the Schedule of 
Activities.  Pati ents will receive training on the routine blood glucose monitoring and paper diary  
completion required during the study .  Pati ents shoul d follow the invest igator’s instructions 
related to frequency  of SMBG but should test their glucose a minimum o f 3 times per week and 
I8F-MC-GPGB (a)Clinical Protocol Page 22
LY3298176as specified for determinat ion of 7 -point glucose profiles (see Section [IP_ADDRESS] ).  Eligible pat ients 
will return to the site for some baseline proced ures during the lead -in phase (Visi t 2) and again 
for randomizat ion to treatment and to receive their first dose of study  drug at Visit 3.
After rando mizat ion and the first dose (Visit 3), pati ents will return to the si te for PK collect ion 
just prior to th e second dose (Visit 4).  Patients will  also have a predose PK collection prior to 
Week 8 (Visit 10), Week 12 dose (Visit 11), and Week 26 (Visit 16) dose .  There will be 
postdose PK collect ions after the second dose (PK -specific Visit 5), thi rd dose (PK-specific 
Visit
7), fifth dose (PK -specific Visit 9, and 12 -week dose (PK -specific Visit 1 2)(seeAppendix 
6,Pharmacokinet ics Schedule of Events ).
A safety follow-up visit will occur approximately [ADDRESS_265341] visit (see Section 9.8.1 ).
Throughout the study , patients treated wi th metformin will remain on the same dose they  were 
receiving at Visit [ADDRESS_265342] igato rs (as well as sponsor study team  and m onitors) remain blind to the 
LY3298176, dulaglut ide 1.5mg, and pl acebo treatment assi gnments within each treatm ent group .  
At each dosing occasion, the study  drug will be administered as 1to [ADDRESS_265343] scheduled procedure shown in the Schedule of 
Activities (Secti on2)for the last patient.
5.4. Scientific Rationale for Study Design
Study  GPGB is a Phase [ADDRESS_265344] ive comparator (dulaglut ide 1.5 mg) in Study  GPGB will allow for a direct 
comparison of the safet y and efficac y of QW LY3298176 to an injectable GLP
-1 RA (as well as 
to placebo) over a 6 -month time period.  In addition, effects of the medicat ion on other 
param eters such as circulat ing bio markers, other measures of glycemic control, lipi[INVESTIGATOR_805], and 
various safet y-related assessments will also be determined.  The planned duration of 6 months 
will allow for a more optimal co mpar ison of the body  weight effects of the 2 drugs, as the 
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265345] ion of LY3298176 suggests that treatment with LY3298176 will resul t 
in continued weight loss over a 6 -month peri od.  The data from  this trial will  form the primary  
basis to assess dose/exposure –response o f LY3298176 efficacy for selection o f doses to be 
included in Phase [ADDRESS_265346] benefit –risk 
characterizat ions in T2DM.
The pl acebo arm  was included in order to determine whether any efficacy  or saf ety effects of 
LY3298176 that a re different in magnitude fro m those of dulaglut ide 1.[ADDRESS_265347] 
equivalent to or are also different fro m no treatment (i.e., placebo).
The current study  will enroll patients wi th inadequate glycemic control based on HbA1c values 
ranging from 7 .0% to 10.5%, inclusive.  Similar ranges of screening HbA1c have been used in 
numero us studies of T2DM treatments.
Patients treated with diet and exercise alone, or in combinat ion with stable met formin 
monotherapy (1000 mg/day) , will be enrolled.  Patients on a second oral antihyperglycemic 
medicat ion(OAM) may be also be eligible if the second OAM was discont inued 3 months or 
more pri or to Visit 1 (refer to Section 6.2, 
Exclusio n Cri terion23).  Stable met formin treatment 
for at least 3 months is required to minimize glucose variabilit yprior to study  entry .
5.5. Justification for Dose
LY3298176 doses of 1 mg, 5 mg, 10 mg (titrated), and 15 mg (titrated), administered 
subcutaneously QW, were selected based on the following:
Safety and tol erabilit y of LY3298176 in healt hy subjects and T2DM patient sin the 
Phase 1 study GPGA through doses of 10mg.
The m argin o f safet y forthe 15-mg maximum dose in this study has an exposure mult iple 
of approximately  [ADDRESS_265348] l evel in rat sand monkey sin the 
6-month toxi cology studies.
The 1 mg was selected using PK/PD modeling and is predi cted to achieve LY329817
6 
concentration levels that will demonstrate HbA1c lowering compared with placebo.
The selected dose levels and dose range support a robust dose -exposure –response 
analysis of mult iple safet y and efficacy measures to support select ion of dose(s) of 
LY329817 6 with optimal benefit/risk rat io for further clinical development.
I8F-MC-GPGB (a)Clinical Protocol Page 24
LY32981766.Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening:
Type of Patient and Disease Characteristics
[1] Have T2DM for at least 6 months before screening based on the disease 
diagnosti c criteria ( Appendix 5 , Wo rld Heal th Organizat ion [WHO] 
Classificat ionfor Diabetes) .
[2] Have an HbA1c value at screening of 7.0% and 10.5% and treated with diet 
and exercise alo ne or a stable dose of m etformin (either immediate release or 
extended release, 1000 mg/day and not m ore than the l ocally approved dose )
for at least3months prior to screening /Visi t 1.  Note:  patients from so me 
countries may  be requi red to be on metformin in order to enroll in the 
protocol .
Patient Characteristics
[
3]Male or female pat ients 18 to 75years of age, inclusive
[3a] Male pati ents:
Male patients should be willing to use reliable contraceptive methods 
throughout the study  and for at l east [ADDRESS_265349] injection (see 
Appendix 7 ).
[
3b]Female pat ients:
Female pat ients not of childbearing pot ential due to surgical sterili zation 
(hysterectomy or bilateral oophorectomy  or tubal  ligat ion) or m enopause.
Women with an intact uterus are deemed postmenopausal if they are 45years ol d, 
and
have not taken horm ones or oral  contraceptives within the last y ear 
and had cessat ion ofmenses for at least 1 year,
OR
have had at least 6 months of amenorrhea with fo llicle -stimulat ing 
horm one (FSH) and estradio l 
levels consistent with a postmenopausal 
state (FSH 40mIU/mL and estradio l 30pg/mL ).
I8F-MC-GPGB (a)Clinical Protocol Page 25
LY3298176Female pat ients of child -bearing potenti al (not surgi cally sterilized and between 
menarche and 1 -year postmenopausal) must :
test negative for pregnancy  at Vi sit1 based on a serum pregnancy 
test
AND
if sexually  active, agree to use two forms of effect ive contraceptio n, 
where at least one form is highl y effective for the duration of the trial 
and for 30days thereafter (see Appendix 7 ).
not be breastfeeding.
[4] Have a BMI between 23and 50 kg/m2(inclusive) at screening.
Informed Consent
[5] In the invest igator’s opi[INVESTIGATOR_3078] n, are well mot ivated, capable, and willing to :
perform  SMBG
prepare (with assistance if necessary) study  medicati on
self-inject (with assistance if necessary) up to 4 injections each week
complete study  diary (ies), as requi red for thi s protocol
are receptive to continuing their prestudy  diet, activi ty levels, and 
follow simple dietary  advice as appropriate
[6] Be willing to maintainmetformin dose during the trial , if taking a stable 
dose of met forminat study  entry .  Pati ents experi encing hypoglycemia 
during the study  may have thei r metf ormin dose reduced.
[7] Are reliable and willing to make themselves available for the duration of the 
study , and who will co mply with the requi red study  and dosing visit s and 
abide by  [CONTACT_221035].
[8] Are able and willing to give signed informed consent and h ave given wri tten 
inform ed consent to parti cipate in this study in accordance wi th local 
regul ations and the ethi cal review board (ERB) governing their site.
6.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions
[
9]Have t ype1 diabetes m ellitus.
[10] Have uncontrolled diabetes defined as more than 2 epi[INVESTIGATOR_221011] 6 months pri or to Visit 1.
I8F-MC-GPGB (a)Clinical Protocol Page 26
LY3298176[11] Have had more than 1 epi[INVESTIGATOR_66677], as de fined by [CONTACT_221036] , within 6 months prior to Visit 1, or has a history  of 
hypoglycemia unawareness or poor recognit ion of hypoglycemic symptoms.  
Any pat ient that the investigator feels will not be able to communicate an 
understanding of hypoglycemic symptoms and the appropriate treatment of 
hypoglycemia should also be excluded.
[12] Have a history  of acute or chronic pancreat itis or elevat ion in serum 
lipase/amylase (g reater than 2 times the upper limit of normal [ULN]) or 
fasting serum triglyceride level of >500 mg/dLat screening.
[13] Have a d iagnosis of gastroparesis or history  of bariatri c surgery  or a clinically  
significant gastri c em ptying abnormalit y, in the opi [INVESTIGATOR_88079].
[14] Have a ctive proliferat ive diabetic retinopathy.
[15] Have known liver disease, obvious clinical signs or symptoms of liver disease, 
acute or chronic hepat itis, or alanine aminotransferase (ALT) l evels 
>2.5times the ULN at Vi sit1, as determined by  [CONTACT_221037] .
[16] Have a known self or family  history  (first-degree relat ive) of mult iple 
endocrine neoplasia t ype2A or ty pe2B, thy roid C-cell hyperplasia, or 
medullary  thyroi d carcino ma.
[17] Evidence of h ypothy roidism or hy perthy roidism based on clinical evaluat ion 
and/or an abnormal thyro id-stimulat ing horm one that, in the opi[INVESTIGATOR_3078] n of the 
investigator, would pose a risk to patient safet y.  Subjects on a stable dose of 
thyroid replacement therapy  for at least the prior 3 months who are clinically  
euthy roid and who are anticipated to remain on this dose throughout the trial 
periodmay be eligible if they meet the other criteria.
[18] Have a screening calcitonin 20pg/mL as determined by  [CONTACT_221038] 1.
[19] Have had any  of the f ollowing within the last 6 months prior to screening:
myocardial  infarct ion (MI), unstable angina, coronary  artery  by[CONTACT_9292], 
percutaneous coronary  intervent ion (diagnostic angi ogram s are permitted), 
transi entischemic attack (TIA), cerebrovascular accident or decompensated 
congest ive heart failure , or currently  have [LOCATION_001] Health Associ ationClass 
IIIor IV heart failure .  
[20] Have an electrocardiogram (ECG) considered by  [CONTACT_221039].  A QTc (Fridericia)
interval  greater than 450 ms in men and greater than 470 msin wo men is 
specifically excluded.
[21] Known significant autonomic neuropathy  as evidenced by  [CONTACT_221040],
resting tachycardia, orthostati c hypotensio n, or diabet ic diarrhea.
I8F-MC-GPGB (a)Clinical Protocol Page 27
LY3298176[22] Have a p ersonal or family history  of long QT syndrom e, family history  of 
sudden death in a first -degree relat ive (p arents, sibling, or children) before the 
age of 40years , or a personal history  of unexplained syncope within the last 
year.  Use of prescript ion or over -the-counter medications known to 
significant ly pro long the QT or QTc interval at screening.
[23] Have poorly  controlled hypertension ( i.e., mean seated systolic BP
160mmHg or m ean seated di astoli c BP 95mmHg)at screening , or a 
change in antihypertensive medications within 30 days of screening, renal  
artery  stenosi s, or evi dence of labile BPi[INVESTIGATOR_221012].
[24]Random triglycerides >500 mg/dL ( 5.7mmo l/L).  If the patient i s on 
lipid-lowering therapi[INVESTIGATOR_014], doses must be stable for 30 days prior to screening.
[25] Have an es timated gl omerul ar fil tration rate (eGFR) <45 mL/min/1.[ADDRESS_265350] meet local label requirements.
[26] Have a history  of atopy  (severe or m ultiple allergic manifestati ons) or 
clinically significant mult iple or severe drug allergies, or intolerance to topi[INVESTIGATOR_221013], or severe post -treatment hypersensit ivity react ions (including, 
but not limited to, ery thema m ultiforme maj or, linear immunoglobulin A 
derm atosis, toxic epi[INVESTIGATOR_194], anaphylaxis, angioedema, or 
exfoliative dermat itis).
[27] Have an act ive or untreated malignancy or have been in remission fro m a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcino mas of the cervix, or in situ prostate cancer) for less than 
5years prior to screening .
[28] Have evidence of human immunodefic iency  virus (HIV) and/or posi tive HIV 
antibodies historically or at screening.
[29] Evidence of hepat itisB and/or posi tive hepat itisB surface ant igen or evi dence 
of hepati tisC.
[30] Have a history  of a transplanted organ (corneal transplants [keratoplas ty] 
allowed).
[31] Have evidence of a significant active, uncontrolled medical condit ion or a 
history  of any medical  problem  capable of const ituting a risk when taking the 
study  medicat ion or i nterfering wi th the interpretatio n of data, as judged by 
[CONTACT_221041].
[32] Have had a significant change in weight, defined as a gain or loss of at least 
4kg (9 lb) in the 3 months pri or to screening.
I8F-MC-GPGB (a)Clinical Protocol Page 28
LY3298176[33] Have had a blood donation of [ADDRESS_265351] a 
hemoglo bin value <11 g/dL (males) or <10 g/dL (females), or an y other 
condi tion known to interfere with HbA1c methodology .
[34] Have any other condit ion (including known drug or alcoho l abuse or 
psychiatric disorder) that, in the opi[INVESTIGATOR_1649] o f the investigator, may preclude the 
patient from following and co mpleting the protocol.
Prior/Concomitant Therapy
[35] Withthe exception o f stable doses of metformin, p atients on another OAM 
(including, but not limited to, sulfonylureas, DPP -4i, sodi um–glucose 
cotransport 2 inhibitors, alpha -glucosi dase inhibitors, m eglitinides) in addition 
to metformin therapy may be rando mized if the addit ional OAM treatment 
was discont inued at least 3months pri or to screening.
[36] Have used insulin for diabet ic control within the prior year.  However, short -
term use of insulin for acute condit ions is allowed ( 14days)in certain 
situations,such as during a hospi[INVESTIGATOR_221014] (see 
Secti on7.7)
.
[37] Have had any  exposure to dul agluti de, other GLP -1analogs, or other related 
compounds wi thin the pri or 3 months or any history  ever of allergies to these 
medicat ions.  Pati ents who pre viously took GLP -1 analogs or related 
compounds and who discont inued those medications >3 months prior to 
Visit1 for intol erabilit y or l ack of efficacy  should not be rando mized.
[38] Have been treated or plan to be treated with drugs that promote weight loss 
(e.g., Saxenda [liraglut ide 3.0 mg], Xenical [orlistat], Meridia 
[sibutramine], Acutrim [phenylpropano lamine], Sanorex [mazindo l], 
Api[INVESTIGATOR_82335][phentermine], BELVIQ [lorcaserin], Qsymia 
[phentermine/topi[INVESTIGATOR_82336]], Con trave [naltrexone/bupropi[INVESTIGATOR_2394]] or 
similar other body  weight loss medicat ions including over -the-counter [OTC] 
medicat ions [e.g., allī]) wi thin 3 months prior to Visit 1.
[39] Are receiving chronic (>2 weeks) systemic glucocorticoid therapy (excluding 
topi[INVESTIGATOR_2855], in traocul ar, intranasal, intra -articular, or inhaled preparations) or have 
received such therapy  within 4weeks immediately prior to screening.
[40] Are current ly taking a central nervous system stimulant ( e.g., Ritalin-SR) 
with the excepti on of  caffeinated beverages at screening.
[41] Within [ADDRESS_265352] received treatment with 
a drug that has not received regulatory  approval  for any  indicat ion.  
If the 
previous study  drug has a l ong half -life, 3 months or 5 half -lives (wh ichever is 
longer) should have passed.
I8F-MC-GPGB (a)Clinical Protocol Page 29
LY3298176[42] Have an average weekly alcoho l intake that exceeds 21 units per week (males) 
and 14 units per week (females) [1 unit = 12 oz or 360 mL of beer; 5 oz or 
150mL of wine; 1.[ADDRESS_265353] illed spi[INVESTIGATOR_17040] s].
[43] Evidence of regular use of known drugs of abuse in the opi[INVESTIGATOR_3078] n of the 
investigator.
Prior/Concurrent Clinical Trial Experience
[44] H ave previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ingLY3298176 .
[45]Previous exposure or known allergies to LY3298176.
[
46]Are current ly enrolled in any other clinical trial invo lving an invest igational 
product or any  other type of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
Other Exclusions
[47] A re invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[
48] A re Eli Lilly and Co mpany empl oyees or ar e employees of any third party  
involved in study  who requi re exclusio n of their emplo yees.
[49]Are, in the opi[INVESTIGATOR_3078] n of the invest igator or sponsor, unsuitable for inclusio n in 
the study .
6.3. Lifestyle Restrictions
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study  or 
for 8 weeks following the study .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failures) may be 
rescreened only once at the discret ion of the investigator.  Before rescreening is performed, the 
patient m ust si gn a new informed consent form (ICF) and receive a new ident ification number.   
If, in the opi[INVESTIGATOR_3078] n of the invest igator, an ineligible lab test result is th e resul t of an error or 
extenuat ing circumstance, then that parameter can be retested once (if feasible wit hin the t ime 
constraints of the screening period) without the patient having to be rescreened.
  However, 
screen failures for HbA1c may not be reteste d or rescreened.
I8F-MC-GPGB (a)Clinical Protocol Page 30
LY32981767.Treatments
7.1. Treatments Administered
This study  will evaluate 4 parallel dose groups of LY3298176 at SC dose levels of 1mg, 5mg,
10mg,and 15mg QW for up to 26 weeks and the resul tswillbe compared with those f or 
dulaglut ide 1.5 mgand placebo.   The study  design is co mposed of 6 parallel treatment groups 
(approx imately 45patients per group).  One treatment group will receive LY3298176 placebo 
and placebo for dulaglut ide.  One treatm ent group will receive act ive dulaglut ide 1.[ADDRESS_265354] ion of dulaglut ide p lacebo after the titration period 
(Table GPGB .2).  All 
SC dose administrations of LY3298176 and dulaglutide should be in different quadrants of the 
abdomen.
This study  involves dose titration in 5-mg increments for doses above 5 mg (Table GPGB. 3).  
Although the invest igator and patients will know dose group assignment (LY3298176 1 mg, 
5mg, 10 mg, or 15 mg) due to the study drug dose volume and titration scheme, they will not 
know whether they  are actually receiving placebo, LY3298176, or dulaglutide.  Thus, patients 
may be titrating placebo.  In t he descript ion of the titration below, please note patients may 
receive LY3298176 or a complementary  dose vol ume of placebo.
Patients assigned to the [ADDRESS_265355] and second doses (Visits 3 and 4).  Pati ents assigned to the [ADDRESS_265356] dose (Visit 6), and the patients assigned [ADDRESS_265357] received the target dose for 2 weeks but still 
are unable to tolerate that dose level (have vo miting or moderate to severe nausea), may have the 
dose reduced by  5mg (10 -mg pat ients woul d receive 5 mg and 15 -mg patients would receive 
10mg) and may remain on the reduced dose for the remainder of the study .  The dose the patient 
administer seach week shoul d be recorded on the case report form ( CRF ) during ti tration and 
throughout the s tudy.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265358] A dministration and Treatment Regimens
Total Number of Injections
Randomization LY3298176 PBO LY3298176 Dulaglutide 1.5 mg SDPPBO Dulaglutide 
SDP
LY 1mg 1 0 0 1
LY 5 mg 1 0 0 1
LY 10mg 2 0 0 1
LY 1 5mg 3 0 0 1
Dulaglutide 1.5 mg 0 Up to 3 1 0
PBO 0 Up to 3 0 1
Abbreviations:  LY = LY3298176 ; PBO= placebo; SDP = single -dose pen.
Table GPGB. 3. Recommended Dose Titration Schedulea
Study Phase Randomization Treatment Phase
Visit 3 4 6 N/S 8 N/S N/S N/S 10–16
Day 0 7 14 21 28 35 42 49 56–182
Week of Treatmentb0 1 2 3 4 5 6 7 8–26
Dose Number 1 2 3 4 5 6 7 8 9–27
LY 1-mg Group 1 1 1 1 1 1 1 1 1
LY 5-mg Group 5 5 5 5 5 5 5 5 5
LY 10-mg Group 5 5 10 10 10 10 10 10 10
LY 1 5-mg Group 5 5 10 10 10 10 15 15 15
Abbreviation s:  LY = LY3298176 ; N/S = none scheduled .
aThis is the recommended titration time course.  The dose utilized should be captured on the study drug CRF.
bThere are no scheduled visits for Weeks 3, 5, 6,and 7 dosing.  The investigator should give the patient the 
expected titration dose for Week 3 at the Week 2 visit (Visit 6) and for Weeks 5- 7 at the Week 4 visit (Visit 8).   
However, for any titration week, the investigator may have the pa tient come to the site for an unscheduled visit to 
dilute the vials and self -administer the study drug under study site supervision.  If a patient does not tolerate a 
target dose level for [ADDRESS_265359] igator believes that the 
patient will not tolerate the dose with further exposure, the investigator may decrease the dose by 5 mg and the 
patient should remain at that dose level for the duration of the study (see Section 7.4for additional discussion on 
dose modification).
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265360] ions of the study  drug by 
[CONTACT_221042] 1 single- dose pen (SDP) inject ion of dulaglutide or matching placebo 
themselves. Patients shoul d inject study  drug and SDP inject ions on the same date and at 
approximately  the same t ime.  The study  site will send vials , diluent, syringes , needles, and SDP s
home with pat ients.  Patients will be dilut ing the vials and self -injecting at home during weeks 
without a clinical site visit and instructions will be provided.  For all clinical site visit s other than 
PK-specific visits, the patient should dilute the v ials and administer the study  drug (including 
dulaglut ide SDP or matching placebo) at the clinical research site under the supervisio n of study  
personnel in order to reinforce patient understanding and confidence.  The investigator or site 
staff may assist patients wi th vial reconst itution and study  drug injection any other time they  
deem  necessary.
Patients taking background metformin (eit her immediate release or extended release) are 
strongly  encouraged to remain on the same ty pe of metformin during the t rial, if possible.  
Changing formulat ions or m anufacturers of metformin during the study  parti cipati on shoul d be 
minimized.  If a dose change (i.e., conversio n of extended release to immediate release or vice 
versa) is required, the invest igator should det ermine the most appropriate clinically equivalent 
metformin dose.  The metformin dose should be at least 1000 mg/day and not more than the 
highest dose allowed per local label.
The patient receiving met formin should cont inue the baseline dose of met formin, unless the 
patient experiences documented hypoglycemia, in which case the dose may  be reduced.
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agents to the patient or the 
patient’s legal representative
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study  returning all unused medication to Lilly ,or its desi gnee ,
unless the sponsor a nd sites have agreed that all unused medicat ion is to be 
destroy ed by  [CONTACT_4179], as all owed by l ocal law.
Patients will  be instructed to contact [CONTACT_221043] /she has a com plaint 
or probl em with the study  drug or drug delivery  system  so that the si tuation can be assessed.
7.1.1. Packaging and Labeling
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.   
LY3298176, dulaglutide 1.[ADDRESS_265361] the dose volume appropriate for their 
CCI
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265362] igator.   
 The reconstituted LY3298176 or placebo solut ion 
shoul d be used immediately  after reconsti tution.
Study  drug (including dulaglut ide 1.5 mg)must bestored inarefrigerator at 2 C to 8C (36 F 
to 46F).  Temperature logsmust be maintained toverify correct storage conditions at the 
investigator site, throughout thestudy. Patients shoul d be instructed to store the study  drug in 
their refrigerator but are not required to maintain temperature logs.
Dulaglut ide 1.5 mgor its placebo shoul d be injected in a different quadrant of the abdomen from 
the concomitant LY3298176 orLY3298176 placebo injections .
7.1.2. Medical Devices
The m anufactured medical devices provided for pati
ent use in the study  are dulaglut ide and 
matching placebo SDPs, glucose meters ,and lancet devices .
7.2. Method of Treatment Assignment
A unique 4- digitpatient number will be assigned to each pat ient when the patient signs the ICF.
Patients will be assigned to dulaglut ide 1.5 mg, placebo, or 1 of 4 LY3298176 dose levels.  
Patients who meet all criteria for enrollment will be randomized at Vi sit3 and ass igned to their 
respective treatment arms via IWRS using the fo llowing stratificat ion variables :  baseline HbA1c 
(<8.5%, 8.5%), met formin use (Yes, No), and BMI (<30, 30).  There will be equal 
rando mizat ion to the treatment arms (1:1:1:1:1:1).  However , LY3298176 placebo patients will 
be randomized such that a portion will be rando mized to each cohort in order to receive the same 
dose vol ume as that cohort in order to maintain the study  blind.  For the active dulaglut ide 
1.5mg group, LY3298176 placebo pat ients should also be distributed through the treatment 
groups i n order to maintain the blind.
The rando mizat ion scheme will be performed using IWRS that will ensure balance between 
treatm ent arm s.
7.2.1. Selection and Timing of Doses
Assignment to [ADDRESS_265363]’s CRF. If a dose of study  
drug, including dulaglut ide or its placebo, is missed, the patient should take it as soon as possible 
unless it i s within 72 hours of the next dose, in whi ch case that dose should be skipped and the 
next dose taken at the appropriate time.
CCI
I8F-MC-GPGB (a)Clinical Protocol Page 34
LY32981767.2.2. Specific Restrictions/Requirements
Prior to beginning the study , pati ents will  com plete inform ed consent and baseline tests.
Throughout the study , patients may  undergo m edical assessments and review of compliance wit h 
restri ctions before continuing in the study .
Patients will  report to the clinical research site for safet y assessments and will remain in the 
clinic until all procedures for that visit are complete and the inv estigator has deemed it safe to 
release the pati ent from the clinic.  There will be no inpatient stays.   In addition, patients will 
report to the clinical research site for PK -specific visit s (Visits 5, 7, 9, and 12 ).
Meals/Diet –Patients shall fast for a t least 8 hours overnight prior to each outpatient visit where 
fasting samples
are drawn or weight m easurements taken.
Alcohol –Alcoho l will not be permitted 8 hours prior to the dosing day, unt il the pat ient has 
been discharged from the clinical research site.
Exercise –Patients will be advised to maintain their regular levels o f physical act ivity/exercise 
during the study .  When certain study  procedures are in progress at the site, patients may be 
requi red to rem ain recumbent or si tting.
Blood donation –Study  parti cipants shoul d be instructed not to donate blood or blood products 
during the study  or for 8weeks fo llowing the study .
Contraception –Male patients or thei r female partners of child -bearing potenti almust use 
reliable contraception during in tercourse throughout the treatm ent peri od and for [ADDRESS_265364] dose of study  drug (as the risk of LY3298176 tothe unborn fetus is unknown).  Female 
patients of childbearing potential, if sexually act ive, shoul duse two forms of effect ive 
contra ception, where at least one form is highl y effective for the durati on of  the tri al and for
30days thereafter .Please see Appendix [ADDRESS_265365] igator will know which dose 
group (1 mg, 5 mg, 10 mg, or 15 mgLY3298176) t he patient is assigned to, they will not know 
whether the patient is receiving LY3298176, dulaglut ide 1.5 mg, or placebo.
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment assignments before the study  is complete.
Emergency  codes, generated by  a com puter drug -labeling system, will be available to the 
investigator.  These codes, which reveal the patient’s treatment group when opened, may be 
opened during the study  ONLY if the patient’s well-being requires knowledge of the patient’s 
treatm ent assignment.
Emergency  unblinding for AEs may be perform ed through theIWRS , which m ay supplement or 
take the place of emergency  codes generated by  a com puter drug -labeling system.  This option 
may be used ONLY if the patient’swell-being requires knowledge of thepatient’streatm ent 
assignment.  All calls result ing in an unblinding event are recorded and reported by  [CONTACT_8784] .
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265366] obtain specific approval fro m a Lilly clinical research 
physician (CRP) for the patientto continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a decisio n.  If the investigator decides that unblinding is warranted, 
the invest igator should make every effort to contact [CONTACT_81108] a patient’s 
treatm ent assi gnment unless thi s coul d delay  emergency treatm ent of the pati ent.  If a pati ent’s 
treatment assignment is unblinded, Lilly must be notified immediately.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee .
7.4. Dosage Modification
Adjustment in study  drug dose level will be allowed for patients assigned to the LY3 [ADDRESS_265367] igator may 
drop the dose back to the next lower dose.  Thus, if a patient has reached the target dose of 
10mg and has vo miting or moderate to severe nausea for 2 weeks, then the patient’s dose level 
may be dropped back to [ADDRESS_265368] ion7.7.
7.5. Preparation/Handling/Storage/Accountability
The study  site must store the study  drug in a l ocked and secure environment. The study  drug 
must be refrigerated (not frozen) at 2 C to 8 C. Dry ice shoul d not be used for cooling. Patients 
will be provided with double -blinded vials containing lyophiliz ed LY3298176 or LY3298176 
placebo and Sterile Water for Inject ion (along wi th sy ringes) and SDPs containing dulaglut ide or 
dulaglut ide placebo , at clinic visit s according to the Study  Schedule. The patients will also 
receive insulated bags wit h cooling ge l packs for use in transporting the study  drug from  the si te 
to the ho me. Study  drug in each parti cipat ing country  will be labeled according to the coun try’s 
regul atory  requi rements.
Commercial metformin may be made available during the treatment period t o pati ents who 
entered the trial on this agent. Appropriate use and storage information will be available by 
[CONTACT_221044].
7.6. Treatment Compliance
During the study ,patients will  be asked to return their unused study  drug m aterialsand 
completed di aries to the si te so that th eir com pliance m ay be assessed.
I8F-MC-GPGB (a)Clinical Protocol Page 36
LY3298176Patients who are significant ly noncom pliant will  be permanent ly discontinued from study
medicat ion.  A pati ent will  be considered significant ly nonco mpliant if he /she intentionally 
misses 4 or m oredoses of study  medicati on.  Similarly , a patient will  be consi dered si gnificant ly 
nonco mpliant if he /she is j udged by [CONTACT_221045].
7.7. Concomitant T herapy
Treatment with drugs that are excluded in the entry criteria (Section 6) is not permitted.
The only conco mitant antihyperglycemic medicat ion permitted during this study  is met formin, 
unless glycemic criteria for rescue therapy  are m et (see Section7.8.1 )
.  Metformin treatment 
must be stable for at least 3monthsprior to screening at a daily dose of 1000 mg/day .  Pati ents
who enter the study  on di et and exe rcise al onewill not be allowed to init iate metformin therapy  
after study  entry  unless cri teria for rescue therapy  are met.
Patients who are being treated with met formin upon entering this study  shoul d rem ain on the 
same (or equivalent if switching to sust ained release) met formin dose throughout the course of 
the study unless a change in dose is required to protect patient safet y.
If a patient switches fro m the immediate -release formulation o f metformin to the 
sustained -release form ulation, the change will be on a milligram -per-milligram basis.
In certain situat ions (such as during a hospi[INVESTIGATOR_221014]), i t may be necessary  for 
a pati ent to be treated with insulin(s).  Treatment with insulin will be allowed for up to 
14consecutive days priorto or during the trial.  If a patient requires treatment with insulin for 
more than 14 consecut ive days, that patient will be considered a “rescue” pat ient and m ay rem ain 
in the study  but will  not receive addi tional study  drug.
Doses of ant ihypertensive a nd lipid -lowering therapi [INVESTIGATOR_221015] [ADDRESS_265369] pati ent safety on an emergency  basis ( e.g., hypertensive 
crisis).
Doses of other prescript ion medications ( e.g., thyroxine, estrogen or progesterone replacement, 
or sel ective estrogen receptor modulators) for treatment of concurrent medical condit ions shoul d 
remain constant durin g the study  whenever possible.
Ifthe need for addit ional conco mitant m edicat ion arises, the patient may  be continued in the 
study  on study  medicat ion if, in the invest igator ’s opi[INVESTIGATOR_3078] n, the addit ion of the new medication 
does not pose a safet y risk.If an addit ional concomitant medicatio n is started, the sponsor 
shoul d be informed as soon as possible. Nausea and/or vomit ing during this study  may be 
treated with ant iemetics that do not increase QTc ( e.g., cyclizine ormeclizine) but should not be 
used prophylact ically.  Nonsteroidal ant i-inflammatory  medicat ions (including ibuprofen, 
aspi[INVESTIGATOR_248]),acetaminophen, cough suppressants, ant ihistamines, vitamin/mineral supplements, 
antibiotics, and topi[INVESTIGATOR_2855] o intments may be used on an as -needed basis without notifying the 
sponsor and are not restrict ed by  [CONTACT_221046]. Any addit ional 
I8F-MC-GPGB (a)Clinical Protocol Page 37
LY3298176medicat ion used during the course of the study (including those not requi ring sponsor 
notifications) must be documented on the appropriate electronic case report form ( eCRF) .
Specifically excluded concomitant medicat ions include the following:
Chronic use of drugs that direct ly reduce GImotility including but not limited to 
anticholinergics, ant iemetics, and opi[INVESTIGATOR_858] ( e.g., metocl opramide, phenergan, dicyclo mine, 
and morphine)
Chronic use of medicat ions that directly promote mot ility (e.g., bethanecho l and 
cisapride)
Prescri ption or over -the-coun ter m edicat ions to promote weight loss
Systemic glucocortico id therapy of greater than 14 consecutive days’ duration (with the 
exception of topi[INVESTIGATOR_2855], intranasal, intraocular, intra -articular, and inhaled preparations)
Central  nervous system st imulants ( e.g., Ritalin-SR)
Any drug, other than those provided in this study , that has not received regulatory  
approval .
7.8. Treatment after the End of the Stu dy
7.8.1. Special Treatment Considerations (Rescue Therapy)
Invest igators will be trained on how to apply decisio n criteria for the timing and method of 
intervent ion in patients who do not reach glycemic targets during the 26-week treatment period.  
An addit ional therapeut ic intervent ion shoul d be consi dered in pati ents who meet the fo llowing 
criteria:
The patients are fully co mpliant with assigned therapeutic regimen .
AND
In the absence of any  acute condi tion that rai ses blood glucose either of the fo llowing 
occurs :
o During the first [ADDRESS_265370] -randomization: An average fast ing glucose 
level above 270 mg/dL (15.0 mmo l/L) occurs over at least a 2
-week period 
(at least 4 values/week must be available) .
OR
o Any ti me after the first [ADDRESS_265371] -rando mizat ion:An 
average fast ing glucose level above 240 mg/dL (13.3 mmo l/L) occurs over 
at least a 2 -week period (at least 4 values/week must be available) .
If these condit ions are met ,then pat ients may begin treatm ent wi th another antihyperglycemic 
agent as determined by [CONTACT_9682].   If treatm ent wi th another antihyperglycemic agent is 
instituted, then study  drug shoul d be perm anent ly discontinued.   Pati ents may remain in the stud y 
for safet y follow-up, but the date at which they begin rescue therapy  will be the last date for 
collect ion of efficacy  measures.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265372] igator when a pat ient meets one of the fo llowing condi tions af ter consul tation wi th the 
Lilly -designated m edical m onitor:
Abnorm al liver tests or whena pati ent m eetsone of the fo llowing condi tions:
oALT or aspartate aminotransferase ( AST )>8ULN
oALT or AST >5 ULN for more than [ADDRESS_265373] >3 ULN and total bilirubin level >2 ULN or prothrombin t ime 
>1.5ULN
oALT or AST >3ULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
oAlkaline phosphatase (ALP) >3 ULN
oALP >2.5 ULN and total bilirubin >2x ULN
oALP >2.5 ULN with the appearance of fat igue, nausea, vo miting, right quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Invest igator Decisio n
othe invest igator decides that the patient should be discontinued from the study  
medicat ion
Any medicat ion for wei ght loss is given for m ore than 1 week
Adverse Event
When any one of the following events occur ,Lilly or its designee is to be alerted 
immediately :
oPancreat itis or pancreatic cancer (refer to Secti on9.[IP_ADDRESS] for details)
oEstimated glo merular filtration <30mL/min
oAny severe inject ion site reacti on or [ADDRESS_265374] ion site reactions 
occurring a week or more apart
oAny significant study drug -related hypersensit ivity reacti on
oAny nonfatal major cardiovascular (CV) events (refer to Section [IP_ADDRESS].6 for 
details)
oAny other treatm ent-emergent adverse event ( TEAE ),SAE ,or clinical ly
significant laboratory  value for whi ch the invest igator believes that permanent 
study  drug di scont inuat ion is the appropriate measure to be taken.
If the patient, for any  reason (incl uding protocol -mandated inst itution of  rescue therapy; 
see Section 7.8.1 ), requires treatment for greater than 1week wi th another therapeuti c 
agent that has been demonstrated to be effect ive for treatm ent of diabetes.  Also, a change 
in dose of metformin is not allowed (except for incidences of hypoglycemia; see 
Secti on7.1).  However, a change to an equivalent dose strength fro m immediate -release 
to extended- release (or vice versa) formulat ionis allowed.
I8F-MC-GPGB (a)Clinical Protocol Page 39
LY3298176If the patient intentionally  misses 4 or m ore doses (consecutive or not) of study  
medicat ion or intenti onally or repeatedly takes more than the prescribed dose of study  
medicat ion (see Sect ion9.3).
If the patient develops any exclusion c riteria, such as pregnancy or nursing.
If study  drug i s permanently discontinued, the patient should remain in the study  if possible.
8.1.2. Temporary Discontinuation from Study Treatment
After rando mizat ion, the invest igator may temporarily discont inue study  drug, for exam ple, due 
to an AE ( e.g., nausea and vo miting), a clinically significant laboratory  value , or a natural  
disaster .  If study  drug di scont inuat ion is due to an AE, the event is to be followed and 
docum ented.  Every effort shoul d be made by [CONTACT_221047], as soon as it is safe to do 
so.  The dates of study  drug discont inuat ion and restart will be documented.  P atient 
nonco mpliance should not be recorded as temporary  discontinuat ion of study  drug on the eCRF.  
In the event that the patient requires the discontinuation of the study  drug, he/she may continue 
participat ion in the study, attend all visits ,and under go all protocol procedures ,and patient data 
from the time of discont inuat ion of study  drug will not be included in the primary  analyses.
After study  drug di scont inuat ion, pati ents m ay commence any standard diabetes therapy  in line 
with local or regi onal standards of care, and as considered appropriate by  [CONTACT_17062].
8.1.3. Discontinuation of Inadvertently Enrolled Patients
The cri teria for enrollment m ust be fo llowed explici tly. If the sponsor or invest igator ident ifies a 
patient who di d not m eet enrollmen t criteria and was inadvertent ly enrolled, notified discussion 
must occur between the sponsor CRP/ clinical research scient ist (CRS) and the invest igator to 
determine if the pat ient may  cont inue in the study .  If both agree that it is medically appropriate
to con tinue, the investigator must obtain documented approval from the sponsor CRP/CRS to 
allow the inadvertent ly enrolled pat ient to continue in the study  with or wi thout treatm ent wi th 
the invest igational product.
8.2. Discontinuation from the Study
Some pos sible reasons that may lead to permanent discontinuat ion include the following:
Enrollment in any other clinical trial invo lving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpatible 
with this study
Sponsor decision
oParti cipation in the study  needs to be stopped for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and Good Clinical 
Practice (GCP) .
I8F-MC-GPGB (a)Clinical Protocol Page 40
LY3298176Invest igator decisio n
oThe invest igator decides that the patient should be discontinued fro m the study
Subject decisio n
oThe patient requests to be withdrawn fro m the study .
Patients who discont inue the study  early  will have end -of-study  procedures performed as shown 
in the Schedule of Act ivities (Secti on2).
8.3. Lost to Follow -Up
A pat ient willbe considered lost to fo llow
-up if he /she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
Site personnel, or an independent third party, will attempt to collect the vital status of the patient 
within legal  and ethical  boundaries for all patients randomized, including those who did not get 
investigat ional product.  Public sources may  be searched for vi tal status informat ion.  If vital 
status is determined, this will be documented and the pat ient will not be considered lost to 
follow-up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265375] ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix [ADDRESS_265376] ion2.
9.1.2. Secondary Efficacy Assessments
The fo llowing secondary  efficacy measures will be collected at the times shown in Section2.
Body weight : Patients will be weighed on an electronic scale in a light hospi[INVESTIGATOR_221016] t ime in the morning after an overnight fast and evacuat ion of any 
bowel  and bladder contents (See
 Appendix 8 ).  The scale’s performance will be 
monitored at l east m onthly using standard weights, and records of these assessments will 
be kept in the study  binder.
HbA 1c
FBG
Serum  lipi[INVESTIGATOR_805], circulat ing bio markers (including fasting insulin, glucagon, lipi[INVESTIGATOR_805], free fatty  
acids, glycerol , -hydroxy but yrate, fibroblast growth factor -21[FGF -21], and 
adiponect in).
Waist circumference:  Waist circumference should be measured at the midpo int between 
the lower m argin of theleast palpable rib and the top of the iliac crest .  The patient
shoul d stand wi th feet cl ose together, arms at the side and body  weight evenly  distributed, 
and should wear litt le clothing. The patientshoul d be relaxed, and the measurements 
shoul dbe taken at the end of a normal expi[INVESTIGATOR_57774].  The m easurement shoul d be repeated.  
If the difference between the 2 measurements exceeds 1 cm, the 2measurements should 
be repeated.
[IP_ADDRESS]. Exploratory Efficacy Assessments
Seven -point SMBG profiles consist ing of me asurements obtained before each meal, 
approximately  2hours after each meal, and at bedtime on a day  during the week before 
the scheduled clinic visit.  Patients will record their SMBG levels in their diaries, 
according to instructions.  The complete [ADDRESS_265377] be co llected on a single day.  
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265378] vi a CRF the occurrence and nature of 
each patient’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addi tion, si te personnel  will record any  change in the 
condi tion(s) and any new condi tions as AEs. Investi gators shoul d record thei r assessment of the 
potenti al relatedness of each AE to protocol procedure orinvest igational product via CRF.
The invest igator will interpret and document whether or not an AE has a reasonable p ossibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause -and-effect rel ationship between the 
investiga tional product, study  device ,and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
In addit ion to records of observat ions made at specific t imes, unexpected signs and symptoms 
and conco mitant m edicati ons will be r ecorded in the clinical trial records throughout the study .
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
I8F-MC-GPGB (a)Clinical Protocol Page 43
LY3298176If a patient’s investigational pr oduct is di scontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via CRF, clarifying if possible the circumstances leading 
toany dosage modificat ions or discont inuat ionsof treatm ent.
If the AE or SAE is believed to have been caused by  a device i ssue, in addit ion to recording the 
relatedness in the CRF, a product complaint must also be reported.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
Death
Initial or p rolonged inpat ient hospi [INVESTIGATOR_3094]
Alife-threatening experience ( i.e., immediate risk of dying)
Persistent or si gnificant disabilit y/incapacit y
Congeni tal anom aly/bi rth defect
Considered significant by  [CONTACT_92355]:  important 
medical events that may not result in death, be life threatening, or require 
hospi [INVESTIGATOR_221017], based upon appropriate medical 
judgment.
When a condit ion related to the invest igational device necessitates medical or 
surgi cal interventi on to precl ude ei ther perm anent impai rment of  a body  function 
or perm anent dam age to a body  structure, the serious outcome of “required 
intervent ion” will be assigned.
Although all AEs occurring after signing the ICF are recorded in the CRF, SAE reporti ng begins 
after the pati ent has signed the ICF and has received invest igational product.  However, if an 
SAE occurs after signing the ICF, but prior to receiving invest igational product, it needs to be 
reported ONLY if it is considered reasonably po ssibly related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_265379] igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed by[CONTACT_221048] n on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.
Pregnancy (during maternal or paternal exposure to invest igational product) does not me et the 
definit ion of an AE.  However, to fulfill regulatory requirements ,any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in s ubjects once they  have 
discontinued and/or completed the study  (the patientsummary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she cons iders the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
I8F-MC-GPGB (a)Clinical Protocol Page 44
LY32981769.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are serious event s that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
[LOCATION_002] [ADDRESS_265380] ive 2001/20/EC and the 
associ ated detailed guidances or nati onal r egulatory  requirements in parti cipat ing countries 
requi re the reporting of S[LOCATION_003]Rs . Lilly has procedures that will be fo llowed for the recording 
and expedited reporting of S[LOCATION_003]Rs that are consistent with glo bal regulat ions and the associated 
detailed guida nces.
[IP_ADDRESS]. Adverse Events of Special Interest
The fo llowing Adverse Events of Special Interest (AESIs) of varying clinical significance will be 
used to determine the tolerabilit y of LY3298176 over the range of doses selected for this clinical 
trial.  All  AESIs shoul d be captured and reported to Lilly  on the AEeCRF or on a specific eCRF, 
if applicable (see below).  Any AESI that meets the definit ion of an SAE (see Secti on9.2.1 ) 
must be reported as an SAE.
When any one of the following events occur ,Lilly or its designee must be alerted immediately, 
whether it is assessed as an SAE or not:
Confirmed pancreat itis or pancreatic cancer
Any severe inject ion site reacti on or [ADDRESS_265381] ion site reactions 
occurring a week or more apart
Any study  drug -related hy persensi tivity react ion
Any other TEAE, SAE, or clinically significant laboratory  value for which the 
investigator believes that permanent study  drug di scontinuat ion is the appropriate 
measure to be taken.
[IP_ADDRESS].1. Injection Site Reactions
All injecti on si te reacti ons and information regarding their time o f day, time relative to injection, 
size, am ount of ery thema, indurat ion, and pruritus, as well as severit y, will be recorded on 
specific CRFs.  In addition, if the react ion is clinically significant, the site shoul d attem pt to 
contact [CONTACT_221049]-up procedures .  Injection site react ions do not need to be 
recorded as AEs as well unless they  meet SAE criteria.
[IP_ADDRESS].2. Hypersensitivity Reactions
All hypersensit ivity react ions will be reported by  [CONTACT_82389], if any serious 
criterion is met, as SAEs.  Study  drug shoul d be temporarily discont inued forany individual 
suspected of  having a severe or serious allergic/hypersensit ivity react ion to study  drug.  Study  
drug m ay be restarted if, in the opi[INVESTIGATOR_3078] n of the investigator, the event was not related to study  
drug and when/if it is safe to do so.  If study  drug is perm anent ly discont inued, the patient should 
remain in the study .
[IP_ADDRESS].3. Hypoglycemia
Hypoglycemia epi[INVESTIGATOR_134055] a specific eCRF. Informat ion regarding severit y, 
time of day , and invest igator’s opi[INVESTIGATOR_3078] n of relatedness to study drug and procedure will be 
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265382] ed.  Hypoglycemia epi[INVESTIGATOR_221018].  Hy poglycemia will be classified as follows (American Diabetes Associat ion 2005) :
Docum ented Symptomatic Hy poglycemia :  Any t ime a patient feels that he/she is 
experiencing symptoms and/or signs associated with hy poglycemia and has a plasma 
glucose l evel of  3.9mmo l/L (70mg/dL)
Asymptomat ic Hypoglycemia :  An event not accompanied by  [CONTACT_11017][INVESTIGATOR_82344] s of 
hypoglycemia, b ut wi th 3.9mmo l/L (70mg/dL) plasma glucose.
Severe Hypoglycemia :  An epi[INVESTIGATOR_221019], glucagon, or other resuscitat ive act ions.  These epi[INVESTIGATOR_221020].  Plasma glucose 
measurements may  not be available during such an event, but neurological recovery  
attributable to the restoration of plasma glucose to normal is considered sufficient 
evidence that the event was induc ed by  a low plasma gl ucose concentrati on.
Nocturnal  Hypoglycemia :  Any  hypoglycemic event that occurs between bedt ime and 
waking
Probable Symptomat ic Hypoglycemia :  An event during which symptoms of 
hypoglycemia are not accompanied by a plasma glucose determinat ion (but that was 
presum ably caused by a plasma glucose concentratio n 3.9mmo l/L [70mg/dL]) .
[IP_ADDRESS].4. Nausea, Vomiting, and Diarrhea
Nausea, vo miting, and diarrhe a events will be recorded on a specific eCRF.  They  shoul d not be 
recorded as AEs unl ess the event m eetsanSAE criterion.  For each event ,assessment of severit y, 
durati on, and Investigator’s opi[INVESTIGATOR_1649] o f relatedness to study  drug and protocol procedure wil l be 
captured.
[IP_ADDRESS].5. Acute Pancreatitis
Acute pancreat itis is defined as an AE of interest for this study. Acute pancreat itis is an acute 
inflammatory  process of the pancreas that may  also involve peripancreat ic tissues an d/or rem ote 
organ sy stems (Banks et al. 2006) . The di agnosis of acute pancreatit is requires 2 of the fo llowing 
3 features:
abdo minal pain, characterist ic of acute pancreat it
is (generally located in the 
epi[INVESTIGATOR_82347] [Banks 
etal. 2006; Ko izumi et al. 2006] ; the pain is often associated with nausea and 
vomiting);
serum  amylase (total and/or pancreatic) and/or lipase 3ULN;
characterist ic findings of acute pancreat itis on computed tomography  (CT) 
scan or magnet ic resonance imaging (MRI) .
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lipase) should be obtained via the central laboratory  (and l ocally, if needed). 
Imaging studies, such as abdo minal CT scan with or without con trast, MRI, or gallbladder 
ultrasound, should be performed.  If laboratory  values and/or abdominal imaging support the 
diagnosis of acute pancreat itis, the patient must discontinue therapy wit h invest igational product ,
I8F-MC-GPGB (a)Clinical Protocol Page 46
LY3298176but will cont inue in the study  on another glucose -lowering regimen (see Sect ion7.8.1 for details 
on rescue intervent ion).  The most appropriate diabetes therapeutic regimen will be decided by 
[CONTACT_3170], based on the patient’s clinical status.  A review of the patient’s conco mitant 
medicat ions should be conducted to assess any  potent ial causal relat ionship with pancreat itis.
Each case o f AE of pancreat itis must be reported. If typi[INVESTIGATOR_10926]/or symptoms o f 
pancreat itis are present and confirmed by [CONTACT_11018] (lipase or amylase [total and/or 
pancreat ic]) and imaging studies, the event must be reported as an SAE. For a potential case that 
does not m eet all of these criteria, it is up to the investigator to determine the seriousness of the 
case (AE or SAE) and the relatedness o f the event to study  drug.
In addit ion to the diagnostic assessment in patients who develop symptoms o f acute pancreatit is, 
each patient will have measur ements of pancreat ic amylase and lipase at screening, baseline, and 
at each non -PK-specific visit to assess any  potenti al effects of LY3298176 on the exocrine 
pancreas (refer to Section 2, Schedule of Act ivities).  Further diagnostic assessment per Lilly 
algorithm for assessment of asymptomat ic pancreatic hyperenzymemia will be required 
whenever lipase and/or pancreatic amylase are 3ULN at any time during the study .  If this 
situation occurs at Visit 801 (Week 30), the patient will be required to undergo this addit ional 
workup, and the data will be co llected in the clinical trial database.
All suspected cases of acute or chronic pancr eatit
is, as well as cases of confirmed lipase or 
pancreat ic amylase values 3ULN, will be adjudicated by [CONTACT_221050]. In addit ion, AEs of severe or serious abdo minal pain o f unknown et io
logy will also 
be submitted to th e adjudication co mmittee to assess for possible pancreat itis or other pancreatic 
disease. Relevant data from  patients wi th acute or chronic pancreat itis, those with severe or 
serious abdo minal pain, and those that undergo addit ional assessments due to con firmed 
hyperenzymemia will be entered into a specifically designed eCRF page by  [CONTACT_221051]. The adjudicat ion committee representative will enter the results of adjudicat ion in a 
corresponding eCRF page.
[IP_ADDRESS].6. Major Adverse Cardiovascular Events
Deaths (CV and non -CV), nonfatal MIs, supraventricular arrhy thmias, and nonfatal strokes that 
occur during the treatment period or follow -up period will be adjudicated by  [CONTACT_221052] a study -specific adjudicat ioncharter.  Investigative 
sites will also be asked to submit any  cases of TIA or hospi[INVESTIGATOR_221021].  Hospi[INVESTIGATOR_221022] (such as coronary  artery  by[CONTACT_221053]) will also be submitted for adjudicat ion.
Cardi ovascular event definit ions will be based on the Standardized Definit ions for 
Cardi ovascular and Stroke Endpoint Events in Cli nical Tri als (Hicks et al . 2015) and the 
ESC/ACCF/AHA/WHF Expert Consensus Document Third Universal Definit ion of Myocardial  
Infarct ion (Thygesen et al . 2012) .  An adjudicat ion committee will enter the results of 
adjudicat ion in the corresponding eCRF page .
I8F-MC-GPGB (a)Clinical Protocol Page 47
LY32981769.[IP_ADDRESS]. Thyroid C -Cell Hyperplasia and C -Cell Neoplasms
Individuals with personal or family history  of certain thyro id or nonthyro id endocrine 
abnorm alities or certain preexist ing laboratory  and genet ic characterist ics will be excluded fro m 
the study  (see Secti on6.2).  The assessment of thyroid safety  during the tri al will include 
reporting of thy roid TEAEs and m easurements of calcitonin according to Section2at screening, 
baseline, and Visit s11 and 16 (Months 3 and 6) or ET vi sit.  The purpose of cal citonin 
measurements is to assess the potential o f LY3298176 to affect thy roid C-cell function, which 
includes development of C -cell hyperplasia and neoplasms.
Patients who develop serum calcitonin increases 50% of the me an of the baseline and screening 
values AND an abso lute value 20pg/mL and <35 pg/mL at Visit s11 and 16 (Months 3 and 6) 
will be asked to repeat the measurement within 1 month.  If this repeat value is increasing ( 10% 
increase), the patient will be enco uraged to undergo additional endocrine assessment and longer
term follow-up by  [CONTACT_221054] a seri ous adverse effect on the gland.
Patients wi th an increase in serum calcitonin 50% of  the m ean of  the baseline and screening 
values AND an a bsolute value 35pg/mL at Vi sits9 and 12 (Months 3 and 6) will be 
recommended to immediately undergo addit ional endocrine assessments and longer term 
follow-up by  [CONTACT_82387].
For pati ents who requi re addi tional endocrine assessment because of inc reased calci tonin 
concentration per criteria provided in this sect ion, data from the fo llow-up assessment will be 
collected in the specific section o f the eCRF.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact [CONTACT_221043] /she has a complaint 
or probl em with the investi gational product or drug delivery  system  so that the si tuation can be 
assessed.
9.3. Treatment of Overdose
For pati ents wi th suspected or confirmed overdose with LY3298176 or dulaglutide, there is no 
specific ant idote.  The patient shoul d be watched for GI symptoms and hypoglycemia.  
Treatment is supportive, depending on the patient’s symptoms.
Refer to the IB for LY3298176 and to the Product Label for dulaglut ide.
9.4. Safety
9.4.1. Electrocardiograms
For each patient, 12-lead ECGs shoul d be collected according to Secti on2. Patients must be 
supi[INVESTIGATOR_17044]  [ADDRESS_265383] ion.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265384] ion of more ECGs than expected at a particular time point is allowed when needed to 
ensure high -quality records.
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the patient is st ill present, to determine w hether the subject meets entry  criteria and for 
immediate subject management, should any clinically  relevant findings be ident ified.  Any 
clinically significant findings fro m ECGs that result in a diagnosis and that occur after the pati
ent 
receives the first dose of the invest igationaltreatment s hould be reported to Lilly  or its designee 
as an AE .  The investigator (or qualified designee) is responsible for determining if any change 
in patient management is needed, and must document his/her review of the E CG printed at the 
time of evaluat ion.
After enro llment, if a clinically significant increase in the QT/QTc interval fro m baseline or 
other clinically significant quantitative or qualitat ive change fro m baseline is identified, the 
patientwill be assessed by [CONTACT_221055] ( e.g., palpi[INVESTIGATOR_814], near syncope, and 
syncope) and to determine whether the patientcan continue in the study .  The invest igator or 
qualified designee is responsible for determining if any change in patientmanagement i s needed 
and must document his /her review of the ECG printed at the time of evaluation fro m at least 1of 
the replicate ECGs from each t ime point.
All digital ECGs will be obtained using centrally  provi ded ECG m achines and will be 
electroni cally transmitted to a desi gnated central ECG laboratory .  The central ECG laboratory  
will perform a basic qualit y control  check ( e.g.,demo graphics and study  details) andthen store 
the ECGs in a database.  At a future time, the stored ECG data may be overread by a cardio logist 
at the central ECG laboratory  for further evaluat ion of machine -read m easurements or to meet 
regul atory  requi rements.
The m achine -read ECG intervals and heart rate may be used for data analysis and report -writing 
purposes, unless a cardio logist overr eadingof the ECGs i s conducted prior to complet ion of the 
final study  report (in which case, the overread data would be used).
In addit ion, for each patient, a single ECG will be recorded at screening and if the patient 
discontinues from  the study  prem aturely ( Secti on2) for immediate patient management. These 
ECGs will be stored at the invest igation site.
Any treatm ent-emergent clinically signific ant ECG finding result ing in a diagnosis shoul d be 
reported as an AE in the eCRF.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265385] ion of blood samples for laboratory  testing, at vi sits where requi red (see
Secti on2). The parti cipant shoul d be requi redto sit quiet ly for 5minutes before vital sign 
measurements are taken. An appropriately sized cuff (cuff bladder encirclin g at l east 80% of the 
arm) shoul d be used to ensure the accuracy  of BP measurements.  The arm used for the BP 
measurement should be supported at heart level. At Visit 1 (screening), to determine which arm 
shoul d be used to collect BP and PR throughout the study , BP and PR will be measured once in 
each arm, and the arm  that had the higher systolic BP shoul d be used to collect all 
3measure ments of both BP and PR at all study  visits.  For each parameter (PR, systolic BP, and 
diastolic BP) , 3measurements will be taken using the same arm ; the recordings should be taken 
at least [ADDRESS_265386] should be reported to Lilly or its 
designee as an AE .
9.4.4. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393] .  In addit ion, the study team will review safet y reports in a blinded fashion according to 
the schedule provided in the Trial -Level  Safety  Review plan.  Lilly will also revi ew SAEs wi thin 
time frames mandated by  [CONTACT_221056].  The Lilly  CRP/CRS will , as appropri ate, consult 
with the functionally  independent Gl obal Patient Saf ety therapeuti c area physician or clinical 
scientist.
In addit ion, specific safet y measures are included in the protocol to ensure appropriate 
monitoring of pancreat ic, thy roid, and liver safet y.  Laboratory  findings that trigger pancreat ic 
and thy roid safet y monitoring per Lilly standards are provided in Sect ions9.[IP_ADDRESS] and
[IP_ADDRESS].[ADDRESS_265387] ion8.1.1 .  If a 
study  patient experiences elevated ALT 3ULN or elevated total bilirubin 2ULN, clinical 
and laboratory  monitoring shoul d be ini tiated by  [CONTACT_3170].  Details for hepat ic monitoring 
depend upon the severit y and p ersistence o f observed laboratory  test abnorm alities.  To ensure 
patient safet y and com ply wi th regulatory  guidance, the invest igator is to consult with the Lilly 
CRP /CRS regarding collect ion of specific reco mmended clinical informat ion and fo llow
-up 
laboratory  tests (see Appendix 4 ).
I8F-MC-GPGB (a)Clinical Protocol Page 50
LY32981769.5. Pharmacokinetics
Blood sam ples f or PK analyses will be collected from all rando mized patients in accordance wit h 
Secti on2and Appendix 6 and at early  terminat ion.  However, only samples from pat ients 
assigned to treatment with LY3298176 will be analyzed for drug concentration.
Predose PK samples will be co llected only at Weeks 1, 8, 12, and 26.
Following dose at Weeks 1, 2, 4, and 12, a postdose PK sample will be collected.  
Patients m ay have thei r PK sample collected any  time within the pre -specified co llection 
window at their convenience.
oAt Weeks [ADDRESS_265388] a PK sample co llected within a time 
window of 1 to 48 hours (within 2 days of dose) .
oAt Week [ADDRESS_265389] a PK sample collected within a time window of  
48 to 72 hours (2 to 3 days postdose).
oAt Week [ADDRESS_265390] a PK sample co llected within a t ime window of 
96 to 168 hours (i .e., any  time between [ADDRESS_265391] pri or to the next dose of study  drug administrati on).  
The patient will be required to come to the site for addit ional PK -specif ic visits 
dependent on the time window of PK sampling.
Date and time o f each sample and the most recent LY3298176 dose prior to PK blood draw must 
be recorded.
Drug concentration informat ion that would unblind the study  will not be reported to study  sites 
or blinded personnel while the study  is blinded.
Bioanaly tical samples collected to m easure study  drug concentrati on will be retained for a 
maximum o f 1year following the l ast pati ent visi t for the study .
9.6. Pharmacodynamics
Samples to evaluate the PD properties of LY3298176 are included in the efficacy  measures and 
not applicable here.
9.7. Pharmacogen etics
9.7.1. Whole Blood Samples for Pharmacogenetic Research
A who le blood sample will be co llected for pharmacogenet ic analys es as specified in Secti on2
where local regulat ions allow.
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variabl e response to LY3298176 and
dulaglut ide,and to investigate genet ic variants thought to play  a rol e in T2DM and related 
complicat ions.  Assessment of variable response may  include evaluat ion of AEs or differences in 
efficacy .  
All samples will be coded wi th the pati ent number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_82394].
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265392] patient visit for the study, or 
for a shorter peri od if local regulati ons and/or ERBs/invest igational review boards impose 
shorter time limit s, at a facilit y selected by  [CONTACT_47551] i ts designee. This retention period enables 
use of new techno logies, response to regulatory  questi ons, and invest igation of variable response 
that may  not be observed unt il later in the devel opment of LY3298176 or after LY3298176 
beco mes commercially available .
Molecular techno logies are expected to improve during the [ADDRESS_265393] ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurements of bio molecul
es, incl uding DNA, RNA, proteins, lipi[INVESTIGATOR_805], 
and other cellular elements.
Serum  and plasma ethylenediaminetet raacetic acid (EDTA) and P800 samples for 
nonpharmacogenet ic biomarker research will be collected at the times specified in the Schedule 
of Activities (Secti on2) where l ocal regul ations allow.
Samples will  be used for research on the drug target, disease process, variable response to 
LY3298176, pathway s associ ated wi th diabetes, mechanism o f action of LY3298176, and/or 
research method or in validat ing di agnost ic tools or assay(s) related to diabetes.
Samples will  be retained for a m aximum  of 
15years after the last patient visit for the study ,or 
for a shorter peri od if local regulations and ERBs impose shorter time limit s, at a facilit y selected 
by [CONTACT_11007] .  This retention period enables use of new techno logies,respon seto regulatory  
questions, and invest igation of variable response that may not be observed unt il later in the 
development of LY3298176 or after LY3298176 becomes commercially available.
9.8.1. Samples for Immunogenicity Research
Samples fro m patients in each treatment arm will be tested for the development of 
treatm ent-emergent LY3298176 antidrug ant ibodies (ADA), defined as [ADDRESS_265394] ivities(Secti on2).
Treatment -emergent posit iveLY3298176 ADA samples will be evaluated for their abilit y to 
neutralize the activit y of assigned treatment (LY3298176 -neutralizing ant ibodies) .  
Positive
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265395] an ADA sample measured at the follow-up visit (Visit801) approximately
1monthafter the last dose of LY 3298176.  A risk-
based approach will be used to monitor 
patients who develop treatment -emergent anti drug ant ibodies (TE -ADA) (defined as >4-fold titer 
increase over baseline) after treatment with LY 3298176.   Clinically sig nificant TE -ADA will be 
defined as any  TE-ADA at the follow -
up visit (Visit801) with :
A high ( 1280) or increasing titer
An associ ation of TE -ADA wit h a m oderate to severe injection site react ionor 
infusio n-related reacti on
Cross-reactive and neutralizing binding of an ADA with endogenous GLP -[ADDRESS_265396] returned to baseline ADA titer 
(defined as A DA t iter wi thin 2- fold of baseline).
Patients fo llowed f or at l east [ADDRESS_265397] ivities of 
Daily Living (APPADL )and Impact of  Weight on Self -Percept ion (IW-SP)questionnaires, 
which are self -rated questi onnaires that provi de standardized measures of patients’ perceived 
current health status .  Patients will co mplete the questionnaire sat the specific clinic visits 
summarized in Section2.  At  these visits, the questio nnaires should be completed before any 
other study  procedures (if the patient is not adversely affected by [CONTACT_221057]) or completed 
after the pati ent has sufficient ly recovered from the preceding visit procedures.
The APPADL questionnaire has demonstrated test–retest reliabilit y, validit y, and 
responsiveness to weight loss in individuals with T2DM, thereby [CONTACT_221058] (Hay es et al . 2011, 2012) .  The APPADL contains 
7items that assess how difficult it is for patients to engage in certain act ivities considered 
to be integral to normal daily  life, such as wal king, standing, and climbing stairs.  Items 
are scored on a 5-point numeric rating scale where 5 = “not at all difficult” and 
1 =“unable to do. ”  A raw overall score is calculated by [CONTACT_221059] 
7items.  A transformed overall score is obtained by  [CONTACT_221060] 
I8F-MC-GPGB (a)Clinical Protocol Page 53
LY3298176score to a 0 to 100 scale.  Higher raw overall scores and lower transformed overall scores 
indicate better abilit y to perf orm activit ies of daily living.
The IW -SP questi onnaire contains 3 items that assess how often the patient’s body  
weight affects how happy they  are with their appearance and how often they  feel 
self-consci ous when out in public (Hayes and DeLozier 2015) .  Items are scored on a 
5-point numeric rating scale where 5 = never and 1 = always.  A raw overall score is 
calculated by [CONTACT_221059] 3 items.  A transform ed total  score i s obtained 
by [CONTACT_221061] a 0 to 100 scale.  Higher raw overall score 
and lower transformed overall score indicate better self
-percepti on.
I8F-MC-GPGB (a)Clinical Protocol Page 54
LY329817610.Statistical Considerations
10.1. Sample Size Determination
Approximately  300 patients will be rando mized to placebo, dulaglut ide, or 1 of 4 LY3298176
treatm ent arm s assuming a 10% dropout rate resulting in approximately  45completers per arm.
The Bayesian approach using a dose –response model with respect to an HbA1c change from 
baseline to 26 weeks will provide approximately 98% probabilit y to show wi th 90% confidence 
that at l east 1 LY3298176 dose has superior glycemic control over placebo with a superiority 
bound of 0.8%.  The sample size also p rovides more than 95% probabilit y to show wi th 80% 
confidence that at least 1 LY3298176 dose has noninferior glycemic control compared wit h 
dulaglut ide from baseline to 26 weeks with a 0.3% noninferiorit y bound. This assumes a change 
from baseline glycemi c effect profile shown in
 Table GPGB. 4, and a standard deviat ion (SD) of 
1.0%.
In addit ion, thi ssample size also provides approximately 89% probabili ty to show wi th 60% 
confidence that at least 1 LY3298176 dose has superi orweight loss compared with dulaglutide 
from baseline to 26 weeks with a superi ority bound of 2
kg.  This assumes a change from 
baseline weight loss profile shown in Table GPGB. 4, and a SD of 6 kg.
Table GPGB. 4
. Dose –Response Assumption Used in Sample Size Determination
Placebo LY 1 mg LY 5 mg LY 10 mg LY 15 mg Dulaglutide
CFBL HbA1c (%) 0% 0.74% 1.17% 1.29% 1.44% 1.28%
CFBL body weight (kg) 0 2.0 3.0 5.0 6.0 2.5
Abbreviations: CFBL = change from baseline ; kg = kilogram; LY = LY3298176 .
10.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined in Table GPGB. 5.
Table GPGB. 5
. Definitions of Populations to Be A nalyzed in Study GPGB
Population Description
Enrolled All participants who sign informed consent.
ITT (intention -to-treat) All randomized patients.
mITT (modified ITT) All randomized patients with at least [ADDRESS_265398]-baseline measurement according to the 
treatment the patients were assigned.
PP (per protocol) All randomized patients who were compliant with study drug and completed the 
protocol .
Safety All randomized participants who take at least 1 dose of study treatment.  Participants will 
be included in the treatment group to which they were randomized.  In the event of a 
treatment error, participants will be analyzed according to the treatment they actually 
received.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265399] ical analysis plan (SAP) and/or clinical study  report.  
Addit ional exploratory  analyses of the data may  be perform ed as deemed appropriate.  Analys es 
will be fully detailed in the SAP.
The intent ion-to-treat (ITT) populat ion is defined as all rando mized pat ients.  Stati stical analyses 
(including the primary analysis) will be conducted on the modified ITT (mITT) populat ion.  The 
mITT populat ion is def ined as all rando mized pat ients with at least [ADDRESS_265400] -baseline measurement 
according to the treatment the patients were assigned.  The per- protocol (PP) populat ion is 
defined as all rando mized patients who were compliant with study drug and completed the 
protocol  and is a subset of the mITT population.  The safet y populati on is defined as all 
rando mized patients who have received at least 1 dose of study  drug.  Safet y analyses will be 
perform ed on the safet y populati on.
Some efficacy measures will also be analyzed on the PP dataset.  The PP analysis will include 
patients who meet the fo llowing addi tional criteria:
Have been appropriately rando mized
Have not discont inued fro m the study  for any  of the early  discontinuati on cri teria
Have not missed 4 or more dos es during the treatment period
Have not been rescued or taken a concomitant ant ihyperglycemic medicat ion besides 
metformin for more than [ADDRESS_265401] had rescue therapy  will be incl uded in the m ITT popul ation, but not the PP 
popul ation. The efficacy measures will be censored at the time o f rescue for analyses using 
mITT populat ion.
No adj ustments for multiplicity will be performed.
All tests of treatment effects will be conducted at a one
-sided alpha level of 0.1 and/or one -sided 
90% confidence interval, unless otherwise stated.
The baseline value used for the analyses will be the last scheduled baseline value obtained for 
each patient prior to randomization.
The primary  analysis of the primary  endpoint and possibly  other Bay esian analyses may be 
computed using Fixed and Adapt ive Clinical Trial Simulator software.  Remaining summaries 
and analyses will be performed using the SAS Sy stem .
I8F-MC-GPGB (a)Clinical Protocol Page 56
LY329817610.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
All patients who disco ntinue the study  will be i dentified, and the extent of their participation in 
the study  will be reported.  If known, a reason for their discont inuation will be given.  The 
primary  reasons for di scont inuat ion will be listed and will be summarized by [CONTACT_221062].  The 
percentage of patients discontinuing fro m each treatment will be co mpared using the Fisher’s 
exact test.
[IP_ADDRESS]. Patient Characteristics
Dem ographic and baseline characterist ics will be summarized by [CONTACT_1570].  Categorical 
variables will be summarized by  [CONTACT_22977].  For categorical variables, 
comparisons between treatment groups will be assessed using a Pearson Chi -Square test.  
Continuous variables will be summarized by [CONTACT_221063].  For continuous variables, 
comparisons between the treatment groups will be performed using a 1- way analysis o f variance 
with treatm ent as the fixed effect.
[IP_ADDRESS]. Concomitant Therapy
Listings and summary of conco mitant therapi[INVESTIGATOR_221023] .
[IP_ADDRESS]. Treatment Compliance
Treatment compliance will be listed using all randomized pat ients and summarized using the 
mITT populat ion.  For a given pat ient, overall co mpliance for treatment period is defined as not 
missing 2 or more consecut ive doses of the assigned treatment or missing 4 or more at any po int 
in the study .  Pati ents who miss 4 or more doses at any po int during the study  will be considered 
significant ly noncom pliant and will be permanently  discontinued from  study  medicat ion.  These 
patients will  not be included in the PP analys is.
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  efficacy  outcome i s HbA1c changes from  baseline to the 26 -week endpoints.
The primary  analyses will  be perform ed on the m ITT analysis set usi ng a Bayesian dose –
response model.  The model will include LY329 8176 doses and placebo.
The Hi erarchical Logistic Model will be used as the dose –response model for HbA1c change 
from baseline to the 26 -week endpo int.  Priors for modeled dose –response will fo llow a norm al 
distribut ion.  Priors for variance will fo llow inverse gamma distribut ions.  The placebo group 
will be modeled with the LY3298176 doses, whereas dulaglut ide will be modeled separately.  
Details o f these pri or distribut ions will be provided in the SAP.
The primary  analysis will consist of this dose –respon se model and examining the probabilit y 
each LY3298176 dose has demo nstrated superiority relat ive to placebo using a superiorit y 
margin o f 0.8%.  Analyses will also consist of the 90% one -sided credible interval for the 
difference in mean response for each LY3298176 dose versus placebo at 26 weeks.  No 
adjustm ent for multiplicity will be performed.  Probabilit ies based on posterior distributions of 
I8F-MC-GPGB (a)Clinical Protocol Page 57
LY3298176each dose group’s mean response exceeding the placebo group’s mean response by [CONTACT_221064] (e.g., by 0.6%) will also be provided.
The l ongitudinal  model will  be the linear regressio n longitudinal model.  The observed 26- week 
endpo int will be modeled using a linear regression model fro m previous t imepoints.  Priors for 
terms in the mean dose –response funct ion will fo llow a normal distribut ion.  Pri ors for vari ance 
will fo llow an inverse gamma distribut ion.  All the doses will be modeled separately using this 
longitudinal model.  Details of these prior distributio ns will be provided in the SAP.
Descript ive statistics by [CONTACT_221065]1c and HbA1c change fro m baseline at the [ADDRESS_265402] ics will be presented by  [CONTACT_221066], mean, SD, median, minimum, and maximum.
[IP_ADDRESS]. Supporting Analys es of Primary Outcome
Supportive analys es of the primary  efficacy outcome for the m ITT dataset will be MMRM using 
restri cted maximum likelihood with m etformin use (y es/no), treatm ent, vi sit, and treatm ent-
by-
visit interaction as fixed effects, HbA1c baseline as a covariate, and patient as a random effect.  
The dependent variable will be the post -baseline change fro m baseline values.  The unstructured 
covariance matrix will be selected init ially.  If the unstructured covariance structure leads to 
nonconvergence, Akaike’s informat ion criterion will  be used to sel ect the best covariance 
structure.  The treatment p- value will be used as evidence o f differenc e between active drug and 
placebo, whereas the com parison of l east-square (LS) means versus placebo (unadjusted for 
multiple comparisons) will provide magnitude and significance of this difference.
A further robustness check will be made using the PP dataset and applying the same MMRM 
procedure as described in the above paragraph.  Any differences in conclusio ns will be further 
investigated by [CONTACT_221067].
The MMRM analysis will be examined for robustness by  [CONTACT_221068]-by-strata and 
treatm ent-by-baseline HbA1c interactions in the MMRM model using the mITT dataset.  If any 
of these checks give posit ive indicat ions, supporti ve analyses account ing for the i dentified issues 
will be co mpared alo ng with th e primary  analysis.
An analysis o f covari ance (ANCOVA) m odel will be used for the primary  efficacy  outcome for 
the mITT dataset wi th fixed effects of met formin use, treatment, and baseline HbA1c as 
covari ates.  Missing endpo ints will be imputed using last observat ion carri ed forward (LOCF).  
For thi s model, the endpoint i s defined as latest HbA1c measurement obtained for a patient in the 
time interval between rando mization and 26weeks after randomization.
[IP_ADDRESS]. Secondary Analyses
[IP_ADDRESS].1. Secondary Analysis on Primary Ef ficacy Endpoint
The secondary  analysis o f the primary  endpoint will consist of the dose –response model, which 
will also be used to examine the probabilit y that any LY3298176 dose has exhibited 
noninferiorit y in co mpar ison to the dulaglut ide dose using a no ninferiori ty margin o f 0.3%.  Thi s 
analysis will be used for internal business decisio ns.
I8F-MC-GPGB (a)Clinical Protocol Page 58
LY329817610.[IP_ADDRESS]. Analyses on Secondary Efficacy Endpoints
In addit ion to the primary  efficacy analysis of HbA1c, the following secondary  efficacy  
outcom es will  be analyzed on the m ITTpopulat ion:
Body  weight change from  baseline to 12 and 26 weeks
Percentage of patient with 5% or greater body  weight l oss at 26 weeks
Change from baseline o f HbA1c at 12weeks
Percentage of patients with 10% or greater body  weight loss at 26 weeks
Percentage of patients reaching the HbA1c target of 6.5% and of 7.0%
Change from baseline o f FBG at 12 and 26 weeks
Change from baseline o f waist circumference at 12 and 26 weeks
The m ean weight change at 12 and 26 weeks as well as the 12-week HbA1c endp oint will be 
analyzed using a similar dose –response model as the primary endpoint.  HbA1c will cont inue to 
be analyzed using a superiorit y bound of 0.8% to placebo as well as a noninferiorit y bound of 
0.3% relative to dulaglut
ide.  The weight change from baseline at both 12 and 26 weeks will use 
a superi ority bound of 2.0kg.  In addit ion, supportive analys es of the mean weight change for the 
mITT dataset will be the MMRM similar to that of the primary  efficacy  outcom e.
The percentage of patients with 5% (and wi th 10%) body  weight loss, the percentage of 
patients reaching the HbA1c target of 6.5% (and of 7.0%) at [ADDRESS_265403] ics 
will include sample size, frequency , and percentage.
I8F-MC-GPGB (a)Clinical Protocol Page 59
LY329817610.3.4. Safety Analyses
[IP_ADDRESS]. Clinical Evaluation of Safety
The safet y popul ation will be used for safet y analyses.  Both the o verall and the pairwise 
comparisons of each LY3298176 dose versus placebo and dulaglut ide will be reported for these 
safet y analyses.
Safety measures will include vital signs, body  weight, TEAEs (including SAEs and AEs of 
special interest), laboratory  measures (including anti -LY3298176 ant ibodies), and ECGs.  
Summary  statistics will be presented by  [CONTACT_221069] y measures.
The summary statistics for continuous variables will be sample size, mean, SD, median, 
minimum, and maximum.
The summary stati stics for categorical variables will be sample size, frequency , and percentage.
Exposure to each therapy  during the treatm ent period of the study  will be calculated for each 
patient and summarized by [CONTACT_1570].
In addit ion, the fo llowing safet y outco mes will be analyzed on the mITT populat ion:
Change from baseline to 26 weeks in HDL -C, total cho lesterol, triglycerides, and LDL -C
Change from baseline to [ADDRESS_265404] in, -hydroxy 
butyrate, gl ucagon, and insulin levels
Percentage of patients requiring rescue therapy
The change from baseline of HDL -C, total  chol esterol , triglycerides, LDL -C, fast ing FGF -21, 
adiponect in, -hydroxy but yrate, gl ucagon, and insulin levels will be calculated using a similar 
MMRM -based model to the one used for the primary  analysis.  The corresponding baseline will 
be used in the model instead of the baseline HbA1c levels.  The MMRM model will also include 
a term  for the HbA1c stratificat ion group.
Addit ional analysis, such as concentration –safet y lab plots, may be performed if warranted upon 
review of the data.
[IP_ADDRESS]. Adverse Events
Adverse event s will be listed by [CONTACT_4676], actual term, preferred term, severit y, and rel ationship to 
the treatment.  AEs will be summarized as TEAEs (defined as events that are newly reported 
after randomizat ion or reported to worsen in severity  from baseline).  The incidence of patients 
with at least [ADDRESS_265405] igational 
drug will be summarized by [CONTACT_1570], in addit ion to the incidence of these possibly 
related TEAEs by  [CONTACT_11702].  In addition, a summary  of TEAEs by  [CONTACT_221070].
Reported and adjudicated CV, pancreatic, and thyroid -related AEs will be listed by [CONTACT_4164], and 
if there are a sufficient number of cases they  maybe summarized by [CONTACT_1570].
I8F-MC-GPGB (a)Clinical Protocol Page 60
LY3298176All SAEs will be listed by  [CONTACT_4676].  If a sufficient number of SAEs are reported, incidence 
summaries similar to incidence of TEAEs will be included.
Discontinuati ons due to TEAEs will be listed by  [CONTACT_221071].
In addit ion, exposure –response analyses of TEAEs may  be perform ed if necessary .
[IP_ADDRESS]. Vital Signs
All vital signs will be listed using all randomized patients.
Descript ive statistics for the actual measurements and changes from baseline for s ystolic and 
diastolic BPand PRwill be presented by [CONTACT_31703].  Corresponding figures may be 
presented.
Vital signs will  be analyzed using a similar MMRM -based model as for the secondary  analysis 
on the primary  endpoint.
In addit ion, exposur e
–response analysis o f vital signs may be performed if deemed necessary .
[IP_ADDRESS]. Laboratory Measures
Summary  statistics will be provided for laboratory  measures, by  [CONTACT_765].
A listing of laboratory  measurements for individual patients will be presented by  [CONTACT_765].  An
additional listing will be presented for all laboratory measurements that are outside the normal 
range.
Descript ive statistics for the laboratory analyses will be presented by [CONTACT_6982], 
including safet y off-treatm ent visi ts.
Laboratory  analyses wi th categori cal responses will be summarized by  [CONTACT_221072].
Shift tables will be evaluated at endpoint (LOCF); the maximum/minimum post -baseline 
observat ion (as applicable for a lab) will be compared to the baseline observat ion by [CONTACT_221073].
[IP_ADDRESS]. Evaluation of Immunogenicity
The frequency of ant ibody  formati on to LY3298176 will be determined.  If a neutralizat ion assay  
isperformed, the frequency o f neutralizing antibodies will be determined.  If there are a 
sufficient number of pat ients with posi tive ant ibodies to LY3298176, the change of ant ibodies 
(negat ive to posit ive) will be summarized using shift tables.
The rel ationship between the presence of ant ibodies, antibody t iters, and clinical parameters 
(e.g., AEs, efficacy measures) may  be assessed.  Likewise, the relat ionship between ant ibody  
titers, the PK parameters ,and PD response to LY3298176 may be assessed.
[IP_ADDRESS]. Electro cardiograms
A listing of the individual and averaged ECG measurements, by  [CONTACT_4676], will be produced.  This 
will include the time elapsed between the onset of ventricular depolarizat ion and the end of 
ventri cular repol arizat ion (QT) corrected values describ ed bel ow.
I8F-MC-GPGB (a)Clinical Protocol Page 61
LY3298176Descript ive statistics for the abso lute measurements, outliers, and changes from baseline for 
selected ECG parameters will be presented by [CONTACT_2939].  These include the ECG heart rate, 
and the fo llowing intervals: QT and QT corrected for hea rt rate using Fridericia’s formula 
(QTcF).
In addit ion, LY3298176 concentration –response analysis of QTcF results will be performed as 
well as a categorical analyses of abso lute and change fro m baseline QTc intervals.  Any  
additional ECG analyses will  be detailed in the SAP.
[IP_ADDRESS]. Adverse Events of Special Interest
Hypoglycemia, hypersensit ivity react ions, inject ion site reactions, acute pancreatit is, ma
jor 
adverse CVevents, and selected GI events such as nausea, vo miting, and diarrhea are defined as 
AESIs.
Descriptive statistics for the AESIs will be presented by [CONTACT_6982].  Continuous 
responses will be summarized using sample size, mean, SD, median, minimum, and maximum, 
whereas categori cal responses will  be summarized using frequencies and percentages.
Continuous elements of AESIs, such as the durations o f hypoglycemia and injection site 
reacti ons, will be analyzed using a similar MMRM -based model as for the secondary analysis o n 
the primary  endpoint.
Statistical analyses on categorical AESIs will be analyzed using a logistic regressio n analysis 
with fixed effects of treatment, met formin use, and HbA1c strata.  Addit ional analyses will be 
run if necessary .
[IP_ADDRESS]. Hypoglycemic Epi[INVESTIGATOR_221024]:  docum ented symptom atic hypoglycemia, 
asymptomat ic hypoglycemia, probable symptomatic hypoglycemia, relative hypoglycemia, 
nocturnal  hypoglycemia ,and severe hypoglycemia.  Total or overall hypoglycemia is d efined as 
any event meeting the criteria for documented symptomat ic hypoglycemia, asymptomat ic 
hypoglycemia, or probable symptomat ic hypoglyc emia.
The total hypoglycemia monthly rate per patient will be summarized where 1 month is defined as 
a 30-day period.  Thi s will be calculated by  [CONTACT_221074] 30 days.  Thi s rate will also be 
calculated per pati ent for nocturnal hypoglycemia epi[INVESTIGATOR_1841], and summarized by  [CONTACT_3148].
The incidence and rate of total hypoglycemic epi[INVESTIGATOR_221025] (incidence between visit s) and overall.  Nocturnal hypoglycemia 
epi[INVESTIGATOR_221026]. The incidence of hypoglycemic 
epi[INVESTIGATOR_51953] a time period on treatment is defined as patients with at least 1 hypoglycemic 
epi[INVESTIGATOR_221027].  Statistical analyses will be performed for overall 
total hypoglycemia using a logis tic regressio n analysis wit h fixed effects of treatment, metformin 
use, and HbA1c strata.
I8F-MC-GPGB (a)Clinical Protocol Page 62
LY3298176Listings of hypoglycemic epi[INVESTIGATOR_221028].  If a sufficient number of severe hypoglycemic epi[INVESTIGATOR_1865] s are reported, then 
incidence summaries similar to incidence o f hypoglycemic epi[INVESTIGATOR_221029].
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
LY3298176 concentration data will be analyzed using a populat ion PK approach via nonlinear 
mixed -effects m odeling wit h the NONMEM software. The relationships between LY3298176 
dose and/or concentration and efficacy , tolerabili ty, and safet y endpo ints will be characterized.
Addit ionally , the impact of intrinsic and extrinsic patient factors such as age, weight, ge nder,and 
renal funct ion on PK and/or PD parameters maybe examined as needed.  Ifantidrug ant ibody  
titers are detecte d from immunogenicit y testing, then the impact of immunogenicit y titers on 
LY3298176 PK or any  relevant PD param eters mayalso be examine d.
10.3.6. Other Analyses
[IP_ADDRESS]. Health Outcome/Quality of Life Analyses
Each instrument is transformed to a single score on a scale fro m 0 to 100.  Patient-reported 
outcom es endpo int change fro m baseline at Weeks 12 and 26 will be analyzed using ANCOVA 
with treatm ent, c ountry , metforminuse (Yes/No) , gender, and baseline HbA1c as independent 
variables.   Missing observat ions will be imputed wit h LOCF.  Any  addi tional analysis on 
patient-reported outcomes will be detailed in the SAP.
[IP_ADDRESS]. Subgroup Analyses
Subgroup analyses of important factors, including age, race, ethnicit y, gender, durati on of  
diabetes, baseline HbA1c (<8.5% , 8.5%), met formin use (Yes/No) at baseline, BMI, and other 
factors to be specified in the SAP are planned for the key  outcomes of HbA1c.
These will be c onducted using the ANCOVA model with strata, treatment, factor, 
treatm ent-by-factor interaction as fixed effects, and baseline as covariate.
Other exploratory  subgroup analyses may  be perform ed as deemed appropriate.
[IP_ADDRESS]. Exploratory Analyses
The change from ba seline of 7-point SMBG profiles will be calculated using a similar 
MMRM -based model to the one used for the primary  analysis.  The corresponding baseline will 
be used in the model instead of the baseline HbA1c levels.  The MMRM model will also include 
a term for the HbA1c stratificat ion group.
Statistical analyses on categorical exploratory objectives like the effect of intrinsic factors, such 
as baseline levels of endogenous FGF
-21, GLP -1, or GIP, on the pharmaco logic effects of 
LY3298176 will be done usin g a logistic regression analysis wit h fixed effects of treatment, 
metformin use, and HbA1c strata.
Genet ic markers will be evaluated for their contribution to the variabilit y of LY3298176
pharmaco logy and will also be included as covariates in PK/PD model -based analyses if 
applicable .
I8F-MC-GPGB (a)Clinical Protocol Page 63
LY3298176LY3298176 concentration –response analyses of exploratory  biomarkers m ay be performed.
Exploratory  analysis on efficacy endpo ints such as HbA1c and body  weight m ay be performed 
on dataset that includes data from pat ients who re ceived rescue therapy.
Other exploratory  subgroup analyses may  be perform ed as deemed appropriate .
10.3.7. Interim Analyses
There maybe up to [ADDRESS_265406] co mpleted the treatment part of the study  (prior to com pletion of the 
follow-up phase for all pat ients) and will include all safet y, efficacy , and PK data available 
through the 26- week treatment for all pat ients to confirm Phase 3 doses.
It is not considered a protocol deviat ion if one or more interim analysis is not performed.  
Detailed informat ion on the interim analyses will be specified in an Assessment Committee 
charter or SAP.
I8F-MC-GPGB (a)Clinical Protocol Page 64
LY329817611.References
American Diabete s Associ ation, Workgroup on Hypoglycemia Defining and reporting 
hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia. Diabetes Care . 2005; 28(5):1245–1249.
Baggi oLL, Drucker DJ. Bio logy of incretins: GLP -1 and GIP. Gastroenterology . 
2007;132(6):2131 –2157.
Banks PA, Freeman ML, Practice Parameters Committee of the American Co llege of 
Gastroenterology . Practi ce gui delines in acute pancreatit is. Am J Gastroenterol .
2006;101(10):2379 –2400.
Dungan KM, Povedano ST, Forst T, Gonzalez JG, At isso C, Sealls W, JL Fahrbach. Once 
weekly dulaglut ide versus once -daily liraglut ide in metformin -treated pati ents wi th type 2 
diabetes (AWARD -6): a randomised, open -label, phase 3, non -inferiorit y trial. Lancet . 2014; 
384(9951):134 9–1357.
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety o f once 
weekly dulaglut ide versus insulin glargine in pat ients with type2 diabetes on m etformin and 
glimepi[INVESTIGATOR_14956] (AWARD -2). Diabetes Care . 2015;38(12):2241 –2249.
HayesRP, DeLozier AM. Reliabilit y, validit y, and responsiveness o f the Impact of  Weight on 
Self-Percept ions Questionnaire (IW -SP) in individuals with ty pe2 diabetes and obesit y. 
Diabetes Technol Ther . 2015;17(3):210 –214.
HayesRP, Nel son DR, Meldahl ML, Curtis BH. Abilit y to perform  daily  physical  activi ties in 
individuals wit h type2 diabetes and m oderate obesit y: a preliminary validation o f the Impact 
of Wei ght on Activit ies of Daily Living Quest ionnaire. Diabetes Technol Ther . 
2011;13(7):705 –712.
HayesRP, Schultz EM, Naegeli AN, Curtis BH. Test -retest, responsiveness, and minimal 
important change o f the abilit y to perform physical activit ies of daily living quest ionnaire in 
individuals wit h type2 diabetes and obesit y. Diabetes Technol Ther . 2012;14(12
):1118 –1125.
HicksKA, Tcheng JE, Bozkurt B, Chait man BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, 
Jaff MR, Licht man JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smit h EE, 
Targum  SL, American College of Cardio logy and American Heart Associat ion. 2014 
ACC/AHA Key  Data El ements and Definit ions for Cardi ovascular Endpo int Events in Clinical 
Trials: A Report of the American College of Cardiology /American Heart Associat ion Task 
Force on Clinical Data Standards (Writ ing Co mmittee to Develop Cardiovascular Endpoints 
Data Standards). Circulation
. 2015;132(4):302 –361.
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safet y of 
dulaglut ide in the treatment of ty pe2 diabetes: a com prehensive review of the dulaglut ide 
clinical da ta focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev . 
2016;32(8):776 –790.
KoizumiM, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsuno S. JPN Guidelines for the management of 
acute pancreatit is: diagnostic criteria for acute pancreatit is. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 –32.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265407], for the and for the LEAD -2 Study Group . Efficacy and safet y comparison of 
liraglutide, glimepi[INVESTIGATOR_14956], and placebo, all in co mbination with metformin, in t ype2 diabetes: the 
LEAD (liraglut ide effect and action in diabetes) -2 study . Diabetes Care . 2009;32(1):84 –90.
Nauck MA, Petrie JR, Sesti G, Mannucci E, Courreges JP, Lindegaard ML, Jensen CB, Atkin 
SL, Study  [ADDRESS_265408] igators. A phase 2, randomized, dose -finding study  of the novel once 
weekly human GLP -1 analog, semaglut ide, compared with placebo and open -label liraglut ide 
in patient s with t ype2 diabetes. Diabetes Care . 2016;39(2):231 –241.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chait man BR, White HD, Joint 
ESC/ACCF/AHA/WHF Task Force for the Universal Definit ion of Myocardial Infarction, 
Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax 
JJ, Bonow RO, Pi[INVESTIGATOR_1946] F, G
ibbons RJ, Fox KA, Atar D, Newby [CONTACT_170284], Galvani M, Hamm CW, 
Uretsky  BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Ant man 
EM, Wallent in LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, 
Filippatos G, Luepker RV, Fortma nn SP, Rosamond WD, Levy  D, Wood D, Smi th SC, Hu D, 
Lopez -Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkho menko AN, 
Vasilieva EJ, Mendis S. Third universal definit ion of myocardial infarct ion. Circulation. 
2012;126(16):2020 –2035.
Trulicit y[Summary  of Product Characteristics].  Retrieved December 9, 2016, from 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Product_Information/human/002825/WC500179470.pdf; 2016.
Trulicit y[[LOCATION_002] Package Insert].  Retrieved December 9, 2016 , from 
http://pi.lilly.co m/us/trulicit y
-uspi.pdf; 20 March 2015.
I8F-MC-GPGB (a)Clinical Protocol Page 66
LY3298176Abbreviations and Definitions Appendix 1.
Term Definition
ADA antidrug antibodies
AE Adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporall y associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
APPADL Ability to Perform Physical Activities of Daily Living
AST aspartate aminotransferase
Blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice ve rsa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinic al evaluation of the subjects are 
aware of the treatment received.
BMI body mass index
BP blood pressure
CIOMS Council forInternational Organizations ofMedical Sciences
Com plaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRF case report form
CRP Clinical Research Physician: Individual responsible for the medic al conduct of the 
study.  Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician, or other medical officer.
CRS clinical research scientist
CT computed tomography
I8F-MC-GPGB (a)Clinical Protocol Page 67
LY3298176CTX-1 carboxy -terminal telopeptide of type I collagen
CV cardiovascular
Documented 
symptomatic 
hypoglycemiaDefined as any time a patient feels that he/she is experiencing symptoms and/or signs 
associated with hypoglycemia, and has a plasma glucose level of 3.9mmol/L 
(70mg/dL)
DPP-4i Dipeptidyl peptidase 4 inhibitor (an OAM)
ECG electrocardiogram
eCRF electronic case report form
EDTA ethylenediaminetetraacetic acid
Enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
eGFR estimated glomerular filtration rate
Enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
FBG fasting blood glucose
FGF-[ADDRESS_265409]
HbA1c hemoglobin A1c
HDL-C high-density lipoprotein cholesterol
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
Interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
I8F-MC-GPGB (a)Clinical Protocol Page 68
LY3298176Investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinic al trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT Intentio n to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient (i.e., the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS Interactive Web R esponse Sy stem
IW-SP Impact of Weight on Self -Perception
LDL-C low-density  lipoprotein cholesterol
LOCF last observation carried forward
LS least squares
MAD multiple ascending dose
MI myocardial infarction
mITT modified intent -to-treat
MMRM mixed model for repeated measures
MRI magnetic resonance imaging
OAM oral antihy pergly cemic medication
P1NP procollagen type 1 N -terminal propeptide
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PP Per protocol dataset:  The set of data generated by [CONTACT_221075], according to the underlying scientific model.
PRO patient -reported outcomes
QTc corrected QT interval
QW once w eekly
SAD single ascending dose
SAE serious adverse event
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265410] Characteristics
S[LOCATION_003]R suspected unexpected serious adverse reactions
T2DM type 2 diabetes mellitus
TE-ADA treatment -emergent antidrug antibodies
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, which and does not necessarily have to have a causal 
relatio nship with this treatment.
TIA transient ischemic attack
ULN upper limit of normal (reference range)
USPI [INVESTIGATOR_221030]
I8F-MC-GPGB (a)Clinical Protocol Page 70
LY3298176Clinical Laboratory  Tests Appendix 2.
Clinical Laboratory Testsa
Hematology : Clinical Chemistry:
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) ALP
Neutrophils, segmented ALT
Lymphocy tes AST
Monocytes BUN
Eosinophils Creatinine
Basophils Uric acid
PlateletsCalcium
Total Protein
Hemoglobin A1c Lipase
Amy lase
Urinalysis:eGFRb
pHGlucose, fasting or random
ProteinAlbumin
GlucoseCalcitonin
BloodHormones (females):
Urine leukocyte esterase Pregnancy Test , serum and/or urinec
Urine a lbumin , creatinine , UACR Serum estradiold
Serum FSHd
Lipid Panel (Fasting) Serum LHd
Total Cholesterol
Triglycerides Serologye
HDL -C Hepatitis B Surface Ag
LDL -C (calculated) Hepatitis C Ab
HIV Ab
Immunogenicity Nonpharmacogenetic Stored Samples
Anti-LY3298176 Antibodies EDTA plasma
Anti-LY3298176 antibody neutralization assay Serum
P800 plasma
Pharmacogenetics Sample
Pharmacokinetic Samples Biomarkers
Fasting insulin , C-peptide, glucagon
-hydroxy  buty rate
Adiponectin (Total and HMW)
Optional urine drug screen (local, at the 
discretion of the investigator )FGF-21 (active), GIP and GLP-1 (total and 
active ), osteopontin , free fatty acids, glycerol, 
MCP -1, CTX -1, P1NP, osteocalcin
I8F-MC-GPGB (a)Clinical Protocol Page 71
LY3298176Abbreviations:   Ab = antidrug antibody; Ag = antigen; ALP = a lkaline phosphatase ; ALT = a lanine 
aminotransferase; AST = a spartate aminotransferase; BUN = b lood urea nitrogen; CTX -1 = carboxy -terminal 
telopeptide of type I collagen ;EDTA =ethylenediaminetetraacetic acid; eGFR = estimated glomerular filtration 
rate; FGF -21 = fibroblast growth factor -21; FSH = follicle -stimulating hormone; GIP = glucose -dependent 
insulinotropic peptide; GLP-1 = g lucagon -like peptide -1; H DL-C = high-density lipoprotein cholesterol; 
HIV =human immunodeficiency virus; LDL -C= low -density lipoprotein cholesterol; P1NP = procollagen type 1 
N-terminal propeptide ; RBC =red blood cells; UACR = urine albumin -to-creatinine ratio; WBC = white blood 
cells.
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted .
bEstimated glomerular filtration rate will be calculated by [CONTACT_82409].
cSerum pregnancy test will be performed by [CONTACT_82408] 1 for women of childbearing potential; 
urine pregnan cy tests may be performed at the investigator’s discretion during the study.  A local laboratory may 
be used for urine pregnancy tests.
dPerformed at screening by [CONTACT_221076] .
ePerformed at screening only.
I8F-MC-GPGB (a)Clinical Protocol Page 72
LY3298176Study  Gove rnance Considerations Appendix 3.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265411] igator is responsible for ensuring:
that the patient understands the potential risks and benefits of part icipating in the 
study
that informed consent is given by [CONTACT_57996].  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the adm inistrati on of  
investigat ional product.
answering any quest ions the pati ent m ay have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the pati ent’s 
willingness to continue his /her parti cipati on in the tri al.
Appendix 3. 1.2. Ethical Review
The invest igator or an appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  [CONTACT_221077] (ICH) 
guidelines and other applicable laws a nd regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and dulaglut ide Package Insert or dulaglut ide SmPC, and updates 
during the cou rse of the study
ICF
relevant curri cula vi tae
Appendix 3.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1.consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and CouncilforInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
2.applicable ICH GCP Guidelines
3.applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
I8F-MC-GPGB (a)Clinical Protocol Page 74
LY3298176Appendix 3.1.4. Investigator Information
Physicians with a specialt y in diabetes/endocrinology, internal medicine, or family medicine will 
participate as invest igators in this clinical trial.
Appendix 3.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer wi ll approve the protocol, confirming that, to the best 
of his/her knowl edge, the protocol accurately describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1.6. Final Report Signature
[CONTACT_221083], indicating agreement 
that, to the best of his /her knowl edge, the report accurately  descr ibes the conduct and results of 
the study .
The invest igator with the most enrolled pat ients will serve as the CSR coordinat ing investigator.  
If this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_221078].
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his /her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction son the protocol, the complet ion of the CRFs, and 
study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_221079], tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265412] data or ECG data, will be stored electronically in the central vendor’s 
database system.  Data will subsequent ly be transferred from the central vendor to the Lil ly data 
warehouse.
Any data for which paper documentation provided by [CONTACT_221080] i dentified and documented by  [CONTACT_92366]’s study  file.  Paper 
docum entati on provi ded by  [CONTACT_81146], for example, a paper diary to collect 
patient-reported outcome (PRO) measures ( e.g., a rating scale), a daily dosing schedule, or an 
event di ary.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement system .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPGB (a)Clinical Protocol Page [ADDRESS_265413] Anti-F actin antibody a
GGT Anti-smooth muscle antibody a
CPK
Abbreviations:  ALP = a lkaline phosphatase ;ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; 
CPK = creatinine phosphokinase; GGT = gamma -glutamyl transferase; Ig = imm unoglobulin; 
INR =international normalized ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I8F-MC-GPGB (a)Clinical Protocol Page 77
LY3298176World Health Organization Classification Appendix 5.
for Diabetes
Type 1 Di abetes Mellitus:  Ty pe 1 di abetes m ellitus i s judged to be present when the classical 
symptoms of diabetes (thirst, polyuria, wasting and stupor, or coma) are associated with readily 
detectable concentrations of glucose and ketone bodies in the blood and urine.  Insulin treatment 
is necessary  not only to control  hyperglycemia, but also to prevent spontaneous ketosis and death.
Type 2 Di abetes Mellitus:  Ty pe 2 di abetes m ellitus, al though often asymptomatic, may  also 
present wi th classical  hyperglycemic symptoms (thirst, polyuria, weight loss), but despi[INVESTIGATOR_221031], ketone bodi es are present in only low concentrations in the blood and urine.
Com a is rare in ty pe 2 di abetes, but m ay resul t from extreme hyperglycemia and 
hyperosmo larity; lactic acidosis or ketoacidosis can also occur in fulminat ing illness ( e.g., severe 
infect ion or mesenteric artery  thrombosis) due to acute increase in insulin requirements, but 
spontaneous ketosis does not occur.  Some patients with t ype2 diabetes l ater progress to a state 
of abso lute insulin deficiency.
References :
Albert i KG, Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabetic Med . 1998;15(7):539 –553.
Bennett P. Classificat ion and diagnosis of diabetes mellitus and impaired glucose tolerance. In: 
Pi[INVESTIGATOR_9107] J, William G, editors. Textbook of diabetes. Vol. 1. Oxford: Blackwell Scient ific 
Publicat ions; 1991:p 37 –44.
Report of the Expert Committee on the Diagnosis and Cl assificat ion of Diabetes Mellitus. 
Diabetes Care . 1999;22(suppl 1):S5 –S19.
I8F-MC-GPGB (a)Clinical Protocol Page 78
LY3298176Pharmacokinetics Schedule of Events Appendix 6.
Study Phase ScreenLead -
inRandomize Treatment PhaseFollow
-upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Month of 
treatment0 0 0 0 0 0 112 334 5 6 6 (7)
Week of treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study day/(Dose 
number)±7d 0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13)112/( 17
)140/(21) 168/(25) 182/(27)
PK-specific visit X X X X
PK blood draw X*X X X X * X* X X* X
[I] Predose PK samples will be collected at Visit 4 (Week 1), Visit 10 (Week 8), Visit 11 (Week 12), and Visit 16 (Week 26).  X *= Predose sample.
[II] Postdose PK samples will be collected per the assigned schedule after dosing at Visit 5(Week 1), Visit 7 (Week 2), Visit 9(Week 4),and Visit 12 (Week 12),
and at early termination from all patients.   An early termination PK sample may be taken at any time during the visit.
1.At Visit 5 (Week 1), 1predose PK sample should be collected prior to administering study drug from all patients. Later in the week (Visit 5), an additional 
PK sample should be taken within 1to 48hours (i.e. ,within 2 days of administrating study  drug ).
2.At Visit 7(Week 2), 1PKsample should be collected after administration of the study drug within 1to 48hours (i.e. ,within 2 days of administrating study 
drug).
3.At Visit 9 (Week 4), 1PK sample should be collected after administration of the study drug within 48to 72hours (i.e., 2to 3days after the administration of 
study  drug ).
4.At Visit 12 (Week 12) , 1predose PK s ample should be collected prior to administering the study drug from all patients.  Later in the week (Visit 12), an 
additional PK sample should be taken within 96 to 168 hours (i.e., any time between [ADDRESS_265414] prior to the next dose of 
study  drug administration ).
I8F-MC-GPGB (a) Clinical Protocol Page [ADDRESS_265415] ive form of contracepti on, which can be any  of the fo llowing:
female condo m with spermicide
diaphragm  with spermicide
cervical sponge
cervical cap with spermicide
combined oral contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382]
NuvaRing
implantable contraceptives
injectable contraceptives (such as Depo- Provera )
intrauterine device (such as Mirena and ParaGard )
true abst inence, when in line wit h the preferred and u sual lifestyle o f the pati ent
Men who have had a vasectomy wit h appropri ate postvasectomy documentation of the absence 
of sperm  in the ejaculate are not required to use contraception.  In addition, Inclusion 
Criterion 3b provi des a specific definit ion of w omen not of childbearing potential; these subjects 
will not be required to use contraception.  Male patients with a female partner meet ing the 
definit ion of a wom an not of childbearing potential will not be required to use con tracepti on.
I8F-MC-GPGB (a) Clinical Protocol Page 80
LY3298176World Health Or ganization Standardized Appendix 8.
Protocols for the Measurement of Height and Weight
The fo llowing informat ion has been adapted fro m standardized physical measurement protocols 
for the Worl d Heal th Organizati on’s STEPwi se approach to Surveillance (STEPS) (WHO 2008)
(Available at: http://www.who.int/chp/steps/Part3_Section3.pdf . Accessed August 16, 2016).
Measuring Height
Step 1 Ask the pati ent to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_221081] t when 
their wei ght is measured).
Step [ADDRESS_265416] (stadio meter) or against 
a wall wit h their feet together and their knees straight with their heels against the back b oard or 
the stadi ometer or the wall.
Step 3 Ask the pati ent to l ook strai ght ahead wi thout til ting their head up.
Step 4 Ask the pati ent to breathe in and stand tall. If using a stadiometer or fixed measuring 
device, move the device’s measurement arm gent ly down onto the top of the patient’s head. 
Record the pati ent’s height in cent imeters (cm).
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated scale 
(mechanical or di gital scales are acceptable). All weights for a given pat ient shoul d be m easured 
using the same scale, whenever possible, after the patient has empt ied their bladder. Patients 
shoul d be light ly clothed but not wearing shoes while their weight is measured.
Step 1 Ask the pati ent to remove their fo otwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_221082]).
Step 2 Make sure the scale is placed on a firm, flat, even surface (not on carpet o r on a slopi[INVESTIGATOR_221032] a rough uneven surface).
Step [ADDRESS_265417] their weight in 
kilograms (kg).
I8F-MC-GPGB (a) Clinical Protocol Page 81
LY3298176Protocol A mendment I8F-MC-GPGB (a) Appendix 9.
Summary :A Phase 2 Study  of Once -Weekly LY3298176
Compared with Placebo and Dulaglutide in Patients with 
Type 2 Diabetes Mellitus
Overview
Protocol  I8F-MC-GPGB A Phase 2 Study  of Once -Weekly LY3298176 Co mpared with Plac ebo 
and Dulaglut ide in Patients with Type 2 Diabetes Mellitus has been amended.  The new protocol 
is indicated by  [CONTACT_61504] ( a) and will be used to conduct the study  in place of any  preceding 
versio n of the protocol.
The overall changes and rationale for t he changes made to this protocol are described in the 
following table:
I8F-MC-GPGB (a) Clinical Protocol Page 82
LY3298176Amendment Summary for Protocol I8F-MC-GPGB Amendment ( a)
Section # and Name [CONTACT_19523] 2 Schedule of Activities Visit 13 Study Day/(Dose number) changed from 
98/(15) to 112/(17)Math erro r
Section 6.3 Lifestyle Restrictions 30 days changed to 8 weeks Typographical erro r.  Changing to 8 weeks is 
consistent with Section 7.2.2. Specific 
Restrictions/Requirements
Section 7.6 Treatment Compliance Added “ intentionally ” to the following sentence: A 
patient will be considered significantly 
noncompliant if he/she intentionally misses 4 or 
more doses of study medi cation.  Added to clarify from Section 8.1.2.
Section 8.1.1 Permanent Discontinuation from 
Study TreatmentAdded “significant” to the following bullet:
Any significant study drug- related 
hypersensitivity reaction
Added “ intentionally ” to the following sentence:
If the patient intentionally misses 4 or 
more doses (consecutive or not) of study 
medication or intentionally or repeatedly 
takes more than the prescribed dose of 
study medication (see Section 9.3).Added to clarify and align with Section [IP_ADDRESS].2
Added to clarify from Section 8.1.2
Section 8.1.2 Temporary Discontinuation from 
Study TreatmentAdded “a natural disaster” to the following 
sentence: After randomization, the investigator 
may temporarily  discontinue study drug, for 
example, due to an AE (eg, nausea and vomiting), a 
clinically significant laboratory value, or a natural 
disaster.  Added because we had patients miss doses and 
visits due to hurricanes Irma and Maria, both of 
which have shut sites, resulted in loss of study drug 
due to lack of power/refrigeration, and made it a 
logistical challenge for patients to attend site visits 
ortake study drug.  Since this is not a patient 
compliance issue, we want to keep patients in the 
study.
I8F-MC-GPGB (a) Clinical Protocol Page 83
LY3298176Amendment Summary for Protocol I8F -MC -GPGB Amendment (a)
Section # and Name [CONTACT_19523] 8.1.2 Temporary Discontin uation from 
Study TreatmentSentence deleted: If 4 or more doses of study 
medication (consecutive or not) are missed for any 
reason, then the patient should be permanently 
discontinued from study medication.This sentence has been removed because we are 
allowing patients to miss 4 or more doses when the 
reason has been beyond their control, such as the 
length of time it has taken for follow up for 
abnormal laboratory results and due to natural 
disasters (hurricanes).  Of note, because of 
hurricanes Irma an d Maria we have had sites 
without power and issues of patient logistics that 
have necessitated patients missing doses fully 
beyond their control.  We want to keep those 
patients in the study.
Appendix 6 Pharmacokinetics Schedule of Events Visit 13 Study D ay/(Dose number) changed from 
98/(15) to 112/(17)Math erro r
I8F-MC-GPGB (a) Clinical Protocol Page 84
LY3298176Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
I8F-MC-GPGB (a) Clinical Protocol Page 85
LY32981762. Schedule of Activities
Study Phase ScreenLead -
inRandomiz e Treatment PhaseFollow
upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Week of Treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study Day/(Dose 
number)0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13)[ZIP_CODE]/(
1517)140/(21) 168/(25) 182/(27)
Visit Window (days) ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
PK Specific VisitaX X X X
I8F-MC-GPGB (a) Clinical Protocol Page 86
LY32981766.3 Lifestyle Restrictions
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study  or 
for 30 days 8 weeks following the study .
7.6 Treatment Compliance
During the study ,patients will  be asked to return their unused study  drug m aterialsand 
completed di aries to the si te so that th eir com pliance m ay be assessed.
Patients who are significant ly noncom pliant will be permanent ly discontinued from study
medicat ion.  A pati ent will  be considered significant ly nonco mpliant if he /she intentionally
misses 4 or m oredoses of study  medicati on.  Similarly , a patient will  be consi dered si gnificant ly 
nonco mpliant if he /she is judged by [CONTACT_221045].
8.1.1 Permanent Discontinuation from Study Treatment
oAny significant study drug -related hypersensit ivity reacti on
If the patient intentionally misses 4 or m ore doses (consecutive or not) of study  
medicat ion or intentionally or repeatedly takes more than the prescribed dose of study  
medicat ion (see Sect ion 9.3).
8.1.2Temporary Discontinuation from Study Treatment
After rando mizat ion, the invest igator may temporarily discont inue study  drug, for exam ple, due 
to an AE (e.g., nausea and vo miting), ora clinically significant laboratory value , or a natural  
disaster .  If study  drug di scont inuat ion is due to an AE, the ev ent is to be followed and 
docum ented.  Every  effort shoul d be made by [CONTACT_221047], as soon as it is safe to do 
so.  The dates of study  drug discon tinuation and restart will be documented.  Patient 
nonco mpliance should not be recorded as temporary  discontinuat ion of study  drug on the eCRF.  
If 4 or more doses of study  medicati on (consecut ive or not) are missed for any reason, then the 
patient shoul d be perm anent ly discont inued fro m study  medicati on.
I8F-MC-GPGB (a) Clinical Protocol Page 87
LY3298176Appendix 6 Pharmacokinetics Schedule of Events
Study Phase ScreenLead -
inRandomize Treatment PhaseFollow
-upEarly 
Term
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 801
Month of 
treatment0 0 0 0 0 0 112 334 5 6 6 (7)
Week of treatment 3 2 0 1 1 2 2 4 4 8 12 12 16 20 24 26 (30)
Study day/(Dose 
number)±7d 0/(1) 7/(2) 14/(3) 28/(5) 56/(9) 84/(13)[ZIP_CODE]/(
1517)140/(21) 168/(25) 182/(27)
PK-specific visit X X X X
PK blood draw X*X X X X * X* X X* X
Leo Document ID = 86d2f081-d91d-40be-af2b-9a2f91db9fa2
Approver: 
Approval Date & Time: 28-Nov-2017 15:25:37 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]